{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 3359, "items": [{"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T19:04:10Z", "timestamp": 1575227050146}, "reference-count": 183, "publisher": "Elsevier BV", "issue": "1", "content-domain": {"domain": ["elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Pharmacology & Therapeutics"], "published-print": {"date-parts": [[2013, 10]]}, "DOI": "10.1016/j.pharmthera.2013.05.010", "type": "journal-article", "created": {"date-parts": [[2013, 5, 24]], "date-time": "2013-05-24T15:54:55Z", "timestamp": 1369410895000}, "page": "34-52", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 101, "title": ["Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?"], "prefix": "10.1016", "volume": "140", "author": [{"given": "Ian F.", "family": "Harrison", "sequence": "first", "affiliation": []}, {"given": "David T.", "family": "Dexter", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Pharmacology & Therapeutics"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0163725813001253?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0163725813001253?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 7, 14]], "date-time": "2019-07-14T04:06:40Z", "timestamp": 1563077200000}, "score": 58.03858, "issued": {"date-parts": [[2013, 10]]}, "references-count": 183, "journal-issue": {"published-print": {"date-parts": [[2013, 10]]}, "issue": "1"}, "alternative-id": ["S0163725813001253"], "URL": "http://dx.doi.org/10.1016/j.pharmthera.2013.05.010", "ISSN": ["0163-7258"], "issn-type": [{"value": "0163-7258", "type": "print"}], "subject": ["Pharmacology (medical)", "Pharmacology"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?", "name": "articletitle", "label": "Article Title"}, {"value": "Pharmacology & Therapeutics", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.pharmthera.2013.05.010", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2013 Elsevier Inc. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T07:17:32Z", "timestamp": 1574493452860}, "reference-count": 49, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2011, 1, 12]], "date-time": "2011-01-12T00:00:00Z", "timestamp": 1294790400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["BMC Genomics"], "published-print": {"date-parts": [[2011, 12]]}, "DOI": "10.1186/1471-2164-12-24", "type": "journal-article", "created": {"date-parts": [[2011, 2, 8]], "date-time": "2011-02-08T15:37:30Z", "timestamp": 1297179450000}, "source": "Crossref", "is-referenced-by-count": 30, "title": ["The epigenetic regulator Histone Deacetylase 1 promotes transcription of a core neurogenic programme in zebrafish embryos"], "prefix": "10.1186", "volume": "12", "author": [{"given": "Michael RM", "family": "Harrison", "sequence": "first", "affiliation": []}, {"given": "Aristophanes S", "family": "Georgiou", "sequence": "additional", "affiliation": []}, {"given": "Herman P", "family": "Spaink", "sequence": "additional", "affiliation": []}, {"given": "Vincent T", "family": "Cunliffe", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2011, 1, 12]]}, "reference": [{"key": "3163_CR1", "doi-asserted-by": "publisher", "first-page": "75", "DOI": "10.1146/annurev.biochem.76.052705.162114", "volume": "76", "author": "MD Shahbazian", "year": "2007", "unstructured": "Shahbazian MD, Grunstein M: Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007, 76: 75-100. 10.1146/annurev.biochem.76.052705.162114.", "journal-title": "Annu Rev Biochem"}, {"key": "3163_CR2", "doi-asserted-by": "publisher", "first-page": "206", "DOI": "10.1038/nrm2346", "volume": "9", "author": "XJ Yang", "year": "2008", "unstructured": "Yang XJ, Seto E: The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008, 9: 206-218. 10.1038/nrm2346.", "journal-title": "Nat Rev Mol Cell Biol"}, {"key": "3163_CR3", "doi-asserted-by": "publisher", "first-page": "404", "DOI": "10.1016/j.gde.2008.10.001", "volume": "18", "author": "VT Cunliffe", "year": "2008", "unstructured": "Cunliffe VT: Eloquent silence: developmental functions of Class I histone deacetylases. Curr Opin Genet Dev. 2008, 18: 404-418. 10.1016/j.gde.2008.10.001.", "journal-title": "Curr Opin Genet Dev"}, {"key": "3163_CR4", "doi-asserted-by": "publisher", "first-page": "1412", "DOI": "10.1126/science.1077790", "volume": "298", "author": "A Wang", "year": "2002", "unstructured": "Wang A, Kurdistani SK, Grunstein M: Requirement of Hos2 Histone Deacetylase for gene activity in yeast. Science. 2002, 298: 1412-1414. 10.1126/science.1077790.", "journal-title": "Science"}, {"key": "3163_CR5", "doi-asserted-by": "publisher", "first-page": "437", "DOI": "10.1016/S0092-8674(02)00746-8", "volume": "109", "author": "D Robyr", "year": "2002", "unstructured": "Robyr D, Suka Y, Xenarios I, Kurdistani SK, Wang A, Suka N, Grunstein M: Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases. Cell. 2002, 109: 437-446. 10.1016/S0092-8674(02)00746-8.", "journal-title": "Cell"}, {"key": "3163_CR6", "doi-asserted-by": "publisher", "first-page": "370", "DOI": "10.1038/nature02258", "volume": "427", "author": "E De Nadal", "year": "2004", "unstructured": "De Nadal E, Zapater M, Alepuz PM, Sumoy L, Mas G, Posas F: The MAPK Hog1 recruits Rpd3 histone deacetylase to activate osmoresponsive genes. Nature. 2004, 427: 370-374. 10.1038/nature02258.", "journal-title": "Nature"}, {"key": "3163_CR7", "doi-asserted-by": "publisher", "first-page": "1019", "DOI": "10.1016/j.cell.2009.06.049", "volume": "138", "author": "Z Wang", "year": "2009", "unstructured": "Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K: Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009, 138: 1019-1031. 10.1016/j.cell.2009.06.049.", "journal-title": "Cell"}, {"key": "3163_CR8", "doi-asserted-by": "publisher", "first-page": "645", "DOI": "10.1016/j.cell.2005.03.013", "volume": "121", "author": "N Ballas", "year": "2005", "unstructured": "Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G: REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell. 2005, 121: 645-657. 10.1016/j.cell.2005.03.013.", "journal-title": "Cell"}, {"key": "3163_CR9", "doi-asserted-by": "publisher", "first-page": "2983", "DOI": "10.1242/dev.01166", "volume": "131", "author": "VT Cunliffe", "year": "2004", "unstructured": "Cunliffe VT: Histone deacetylase 1 is required to repress Notch target gene expression during zebrafish neurogenesis and to maintan the production of motoneurones in response to hedgehog signalling. Development. 2004, 131: 2983-2995. 10.1242/dev.01166.", "journal-title": "Development"}, {"key": "3163_CR10", "doi-asserted-by": "publisher", "first-page": "3027", "DOI": "10.1242/dev.01881", "volume": "132", "author": "M Yamaguchi", "year": "2005", "unstructured": "Yamaguchi M, Tomou-Fujimori N, Komori A, Maeda A, Nojima Y, Li H, Okamoto H, Masai I: Histone deacetylase 1 regulates retinal neurogenesis in zebrafish by suppressing Wnt and Notch signaling pathways. Development. 2005, 132: 3027-3043. 10.1242/dev.01881.", "journal-title": "Development"}, {"key": "3163_CR11", "doi-asserted-by": "publisher", "first-page": "883", "DOI": "10.1002/dvdy.20427", "volume": "233", "author": "JA Stadler", "year": "2005", "unstructured": "Stadler JA, Shkumatava A, Norton WHJ, Rau MJ, Geisler R, Fischer S, Neumann CJ: Histone deacetylase 1 is required for cell cycle exit and differentation in the zebrafish retina. Dev Dyn. 2005, 233: 883-889. 10.1002/dvdy.20427.", "journal-title": "Dev Dyn"}, {"key": "3163_CR12", "doi-asserted-by": "publisher", "first-page": "24", "DOI": "10.1016/j.mod.2005.10.005", "volume": "123", "author": "VT Cunliffe", "year": "2006", "unstructured": "Cunliffe VT, Casaccia-Bonnefil P: Histone deacetylase 1 is essential for oligodendrocyte specification in the zebrafish CNS. Mech Dev. 2006, 123: 24-30. 10.1016/j.mod.2005.10.005.", "journal-title": "Mech Dev"}, {"key": "3163_CR13", "doi-asserted-by": "publisher", "first-page": "237", "DOI": "10.1016/j.ydbio.2008.06.040", "volume": "322", "author": "ES No\u00ebl", "year": "2008", "unstructured": "No\u00ebl ES, Casal-Sueiro A, Busch-Nentwich E, Verkade H, Dong PD, Stemple DL, Ober EA: Organ-specific requirements for Hdac1 in liver and pancreas formation. Dev Biol. 2008, 322: 237-250.", "journal-title": "Dev Biol"}, {"key": "3163_CR14", "doi-asserted-by": "publisher", "first-page": "336", "DOI": "10.1016/j.ydbio.2008.02.034", "volume": "317", "author": "M Farooq", "year": "2008", "unstructured": "Farooq M, Sulochana KN, Pan X, To J, Sheng D, Gong Z, Ge R: Histone deacetylase 3 (hdac3) is specifically required for liver development in zebrafish. Dev Biol. 2008, 317: 336-353. 10.1016/j.ydbio.2008.02.034.", "journal-title": "Dev Biol"}, {"key": "3163_CR15", "doi-asserted-by": "publisher", "first-page": "568", "DOI": "10.1016/j.ydbio.2007.10.045", "volume": "313", "author": "MS Ignatius", "year": "2008", "unstructured": "Ignatius MS, Moose HE, El-Hodiri HM, Henion PD: colgate/hdac1 repression of foxd3 expression is required to permit mitfa-dependent melanogenesis. Dev Biol. 2008, 313: 568-583. 10.1016/j.ydbio.2007.10.045.", "journal-title": "Dev Biol"}, {"key": "3163_CR16", "doi-asserted-by": "publisher", "first-page": "7876", "DOI": "10.1073/pnas.0902750106", "volume": "106", "author": "RL Montgomery", "year": "2009", "unstructured": "Montgomery RL, Hsieh J, Barbosa AC, Richardson JA, Olson EN: Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc Natl Acad Sci USA. 2009, 106: 7876-7881. 10.1073/pnas.0902750106.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "3163_CR17", "doi-asserted-by": "publisher", "first-page": "829", "DOI": "10.1038/nn.2333", "volume": "12", "author": "F Ye", "year": "2009", "unstructured": "Ye F, Chen Y, Hoang TN, Montgomery RL, Zhao X, Bu H, Hu T, Taketo MM, van Es JH, Clevers H, Hsieh J, Bassel-Duby R, Olson EN, Lu QR: HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the b-catenin-TCF interaction. Nature Neurosci. 2009, 12: 829-839. 10.1038/nn.2333.", "journal-title": "Nature Neurosci"}, {"key": "3163_CR18", "doi-asserted-by": "publisher", "first-page": "517", "DOI": "10.1038/nrn874", "volume": "3", "author": "N Bertrand", "year": "2002", "unstructured": "Bertrand N, Castro DS, Guillemot F: Proneural genes and the specification of neural cell types. Nat Rev Neurosci. 2002, 3: 517-530. 10.1038/nrn874.", "journal-title": "Nat Rev Neurosci"}, {"key": "3163_CR19", "doi-asserted-by": "publisher", "first-page": "678", "DOI": "10.1038/nrm2009", "volume": "7", "author": "S Bray", "year": "2006", "unstructured": "Bray S: Notch signalling: a simple pathway becomes complex. Nature Rev Mol Cell Biol. 2006, 7: 678-689. 10.1038/nrm2009.", "journal-title": "Nature Rev Mol Cell Biol"}, {"key": "3163_CR20", "doi-asserted-by": "publisher", "first-page": "196", "DOI": "10.1186/1471-2164-9-196", "volume": "9", "author": "SF Krens", "year": "2008", "unstructured": "Krens SF, Corredor-Adamez M, He S, Snaar-Jagalska BE, Spaink HP: ERK1 and ERK2 MAPK are key regulators of distinct gene sets in zebrafish embryogenesis. BMC Genomics. 2008, 9: 196-10.1186/1471-2164-9-196.", "journal-title": "BMC Genomics"}, {"key": "3163_CR21", "doi-asserted-by": "publisher", "first-page": "14863", "DOI": "10.1073/pnas.95.25.14863", "volume": "95", "author": "MB Eisen", "year": "1998", "unstructured": "Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998, 95: 14863-14868. 10.1073/pnas.95.25.14863.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "3163_CR22", "doi-asserted-by": "publisher", "first-page": "3472", "DOI": "10.1002/dvdy.21367", "volume": "236", "author": "SL Gribble", "year": "2007", "unstructured": "Gribble SL, Nikolaus OB, Dorsky RI: Regulation and function of Dbx genes in the zebrafish spinal cord. Dev Dyn. 2007, 236: 3472-3483. 10.1002/dvdy.21367.", "journal-title": "Dev Dyn"}, {"key": "3163_CR23", "doi-asserted-by": "publisher", "first-page": "413", "DOI": "10.1016/j.neuron.2008.07.020", "volume": "59", "author": "SI Wilson", "year": "2008", "unstructured": "Wilson SI, Shafer B, Lee KJ, Dodd J: A molecular program for contralateral trajectory : Rig-1 control by LIM homeodomain transcription factors. Neuron. 2008, 59: 413-424. 10.1016/j.neuron.2008.07.020.", "journal-title": "Neuron"}, {"key": "3163_CR24", "doi-asserted-by": "publisher", "first-page": "551", "DOI": "10.1016/S0896-6273(02)00689-X", "volume": "34", "author": "T M\u00fcller", "year": "2002", "unstructured": "M\u00fcller T, Brohmann H, Pierani A, Heppenstall PA, Lewin GR, Jessell TM, Birchmeier C: The homeodomain factor lbx1 distinguishes two major programs of neuronal differentiation in the dorsal spinal cord. Neuron. 2002, 34: 551-562.", "journal-title": "Neuron"}, {"key": "3163_CR25", "doi-asserted-by": "publisher", "first-page": "829", "DOI": "10.1002/dvdy.21061", "volume": "236", "author": "B Liu", "year": "2007", "unstructured": "Liu B, Liu Z, Chen T, Li H, Qiang B, Yuan J, Peng X, Qiu M: Selective expression of Bhlhb5 in subsets of early-born interneurons and late-born association neurons in the spinal cord. Dev Dyn. 2007, 236: 829-835. 10.1002/dvdy.21061.", "journal-title": "Dev Dyn"}, {"key": "3163_CR26", "doi-asserted-by": "publisher", "first-page": "770", "DOI": "10.1038/nn1706", "volume": "9", "author": "R Mizuguchi", "year": "2006", "unstructured": "Mizuguchi R, Kriks S, Cordes R, Gossler A, Ma Q, Goulding M: Ascl1 and Gsh1/2 control inhibitory and excitatory cell fate in spinal sensory interneurons. Nat Neurosci. 2006, 9: 770-778. 10.1038/nn1706.", "journal-title": "Nat Neurosci"}, {"key": "3163_CR27", "doi-asserted-by": "publisher", "first-page": "1456", "DOI": "10.1128/MCB.01510-07", "volume": "28", "author": "P Mattar", "year": "2008", "unstructured": "Mattar P, Langevin LM, Markham K, Klenin N, Shivji S, Zinyk D, Schuurmans C: Basic helix-loop-helix transcription factors cooperate to specify a cortical projection neuron identity. Mol Cell Biol. 2008, 28: 1456-1469. 10.1128/MCB.01510-07.", "journal-title": "Mol Cell Biol"}, {"key": "3163_CR28", "doi-asserted-by": "publisher", "first-page": "258", "DOI": "10.1016/j.neuron.2008.08.006", "volume": "60", "author": "PS Joshi", "year": "2008", "unstructured": "Joshi PS, Molyneaux BJ, Feng L, Xie X, Macklis JD, Gan L: Bhlhb5 regulates the postmitotic acquisition of area identities in layers II-V of the developing neocortex. Neuron. 2008, 60: 258-272. 10.1016/j.neuron.2008.08.006.", "journal-title": "Neuron"}, {"key": "3163_CR29", "doi-asserted-by": "publisher", "first-page": "817", "DOI": "10.1016/j.neuron.2005.08.030", "volume": "47", "author": "BJ Molyneaux", "year": "2005", "unstructured": "Molyneaux BJ, Arlotta P, Hirata T, Hibi M, Macklis JD: Fezl is required for the birth and specification of corticospinal motor neurons. Neuron. 2005, 47: 817-831. 10.1016/j.neuron.2005.08.030.", "journal-title": "Neuron"}, {"key": "3163_CR30", "doi-asserted-by": "publisher", "first-page": "5857", "DOI": "10.1523/JNEUROSCI.4621-04.2005", "volume": "25", "author": "R Ohsawa", "year": "2005", "unstructured": "Ohsawa R, Ohtsuka T, Kageyama R: Mash1 and Math3 are required for development of branchiomotor neurons and maintenance of neural progenitors. J Neurosci. 2005, 25: 5857-5865. 10.1523/JNEUROSCI.4621-04.2005.", "journal-title": "J Neurosci"}, {"key": "3163_CR31", "doi-asserted-by": "publisher", "first-page": "28492", "DOI": "10.1074/jbc.M400871200", "volume": "279", "author": "T Akagi", "year": "2004", "unstructured": "Akagi T, Inoue T, Miyoshi G, Bessho Y, Takahashi M, Lee JE, Guillemot F, Kageyama R: Requirement of multiple basic helix-loop-helix genes for retinal neuronal subtype specification. J Biol Chem. 2004, 279: 28492-28498. 10.1074/jbc.M400871200.", "journal-title": "J Biol Chem"}, {"key": "3163_CR32", "doi-asserted-by": "publisher", "first-page": "795", "DOI": "10.1016/j.neuron.2004.08.041", "volume": "43", "author": "S Li", "year": "2004", "unstructured": "Li S, Mo Z, Yang X, Price SM, Shen MM, Xiang M: Foxn4 controls genesis of amacrine and horizontal cells by retinal progenitors. Neuron. 2004, 43: 795-807. 10.1016/j.neuron.2004.08.041.", "journal-title": "Neuron"}, {"key": "3163_CR33", "doi-asserted-by": "publisher", "first-page": "4815", "DOI": "10.1242/dev.02664", "volume": "133", "author": "L Feng", "year": "2006", "unstructured": "Feng L, Xie X, Joshi PS, Yang Z, Shibasaki K, Chow RL, Gan L: Requirement for Bhlhb5 in the specification of amacrine and cone bipolar subtypes in the mouse retina. Development. 2006, 133: 4815-4825. 10.1242/dev.02664.", "journal-title": "Development"}, {"key": "3163_CR34", "doi-asserted-by": "publisher", "first-page": "10449", "DOI": "10.1523/JNEUROSCI.3048-09.2009", "volume": "29", "author": "H Jiang", "year": "2009", "unstructured": "Jiang H, Xiang M: Subtype specification of GABAergic amacrine cells by the orphan nuclear receptor Nr4a2/Nurr1. J Neurosci. 2009, 29: 10449-10459. 10.1523/JNEUROSCI.3048-09.2009.", "journal-title": "J Neurosci"}, {"key": "3163_CR35", "doi-asserted-by": "publisher", "first-page": "128", "DOI": "10.1016/j.mod.2008.11.009", "volume": "126", "author": "MJ Ochocinska", "year": "2009", "unstructured": "Ochocinska MJ, Hitchcock PF: NeuroD regulates proliferation of photoreceptor progenitors in the retina of the zebrafish. Mech Dev. 2009, 126: 128-141. 10.1016/j.mod.2008.11.009.", "journal-title": "Mech Dev"}, {"key": "3163_CR36", "doi-asserted-by": "publisher", "first-page": "531", "DOI": "10.1016/S0092-8674(00)80439-0", "volume": "91", "author": "T Furukawa", "year": "1997", "unstructured": "Furukawa T, Morrow EM, Cepko CL: Crx, a novel otx-like homeobox gene, shows photoreceptor-specific expression and regulates photoreceptor differentiation. Cell. 1997, 91: 531-541. 10.1016/S0092-8674(00)80439-0.", "journal-title": "Cell"}, {"key": "3163_CR37", "doi-asserted-by": "publisher", "first-page": "24", "DOI": "10.1016/j.ydbio.2008.12.040", "volume": "328", "author": "SM Nelson", "year": "2009", "unstructured": "Nelson SM, Park L, Stenkamp DL: Retinal homeobox 1 is required for retinal neurogenesis and photoreceptor differentiation in embryonic zebrafish. Dev Biol. 2009, 328: 24-39. 10.1016/j.ydbio.2008.12.040.", "journal-title": "Dev Biol"}, {"key": "3163_CR38", "doi-asserted-by": "publisher", "first-page": "1035", "DOI": "10.1038/nature08797", "volume": "463", "author": "T Vierbuchen", "year": "2010", "unstructured": "Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M: Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010, 463: 1035-1041. 10.1038/nature08797.", "journal-title": "Nature"}, {"key": "3163_CR39", "doi-asserted-by": "publisher", "first-page": "831", "DOI": "10.1016/j.devcel.2006.10.006", "volume": "11", "author": "DS Castro", "year": "2006", "unstructured": "Castro DS, Skowronska-Krawczyk D, Armant O, Donaldson IJ, Parras C, Hunt C, Critchley JA, Nguyen L, Gossler A, G\u00f6ttgens B, Matter JM, Guillemot F: Proneural bHLH and Brn proteins coregulate a neurogenic program through cooperative binding to a conserved DNA motif. Dev Cell. 2006, 11: 831-844. 10.1016/j.devcel.2006.10.006.", "journal-title": "Dev Cell"}, {"key": "3163_CR40", "doi-asserted-by": "publisher", "first-page": "210", "DOI": "10.1016/j.nbd.2010.01.007", "volume": "38", "author": "K Tanji", "year": "2010", "unstructured": "Tanji K, Kamitani T, Mori F, Kakita A, Takahashi H, Wakabayashi K: TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson's disease and dementia with Lewy bodies. Neurobiol Dis. 2010, 38: 210-218. 10.1016/j.nbd.2010.01.007.", "journal-title": "Neurobiol Dis"}, {"key": "3163_CR41", "doi-asserted-by": "publisher", "first-page": "461", "DOI": "10.1016/j.ydbio.2007.09.054", "volume": "312", "author": "B Probst", "year": "2007", "unstructured": "Probst B, Rock R, Gessler M, Vortkamp A, Puschel AW: The rodent Four-jointed ortholog Fjx1 regulates dendrite extension. Dev Biol. 2007, 312: 461-470. 10.1016/j.ydbio.2007.09.054.", "journal-title": "Dev Biol"}, {"key": "3163_CR42", "doi-asserted-by": "publisher", "first-page": "78", "DOI": "10.1186/1471-213X-7-78", "volume": "7", "author": "B Chen", "year": "2007", "unstructured": "Chen B, Cepko CL: Requirement of histone deacetylase activity for the expression of critical photoreceptor genes. BMC Dev Biol. 2007, 7: 78-10.1186/1471-213X-7-78.", "journal-title": "BMC Dev Biol"}, {"key": "3163_CR43", "doi-asserted-by": "publisher", "first-page": "135", "DOI": "10.1038/ng896", "volume": "31", "author": "G Golling", "year": "2002", "unstructured": "Golling G, Amsterdam A, Sun Z, Antonelli M, Maldonado E, Chen W, Burgess S, Haldi M, Artzt K, Farrington S, Lin SY, Nissen RM, Hopkins N: Insertional mutagenesis in zebrafish rapidly identifies genes essential for early vertebrate development. Nature Genet. 2002, 31: 135-140. 10.1038/ng896.", "journal-title": "Nature Genet"}, {"key": "3163_CR44", "doi-asserted-by": "crossref", "first-page": "1395", "DOI": "10.1002/j.1460-2075.1988.tb02956.x", "volume": "7", "author": "TR Hebbes", "year": "1998", "unstructured": "Hebbes TR, Thorne AW, Crane-Robinson C: A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J. 1998, 7: 1395-1402.", "journal-title": "EMBO J"}, {"key": "3163_CR45", "author": "L Weng", "first-page": "1111", "year": "2006", "unstructured": "Weng L, Dai H, Zhan Y, He Y, Stepianants SB, Bassett D: Rosetta error model for gene expression analysis. Bioinformatics. 2006, Oxford, England, 22: 1111-1121. 10.1093/bioinformatics/btl045.", "volume-title": "Bioinformatics"}, {"key": "3163_CR46", "doi-asserted-by": "publisher", "first-page": "470", "DOI": "10.1186/1471-2105-7-470", "volume": "7", "author": "V Beisvag", "year": "2006", "unstructured": "Beisvag V, Junge FK, Bergum H, Jolsum L, Lydersen S, Gunther CC, Ramampiaro H, Langaas M, Sandvik AK, Laegreid A: GeneTools - application for functional annotation and statistical hypothesis testing. BMC Bioinformatics. 2006, 7: 470-10.1186/1471-2105-7-470.", "journal-title": "BMC Bioinformatics"}, {"key": "3163_CR47", "doi-asserted-by": "publisher", "first-page": "3246", "DOI": "10.1093/bioinformatics/bth349", "volume": "20", "author": "AJ Saldanha", "year": "2004", "unstructured": "Saldanha AJ: JavaTreeview-extensible visualization of microarray data. Bioinformatics. 2004, 20: 3246-3248. 10.1093/bioinformatics/bth349.", "journal-title": "Bioinformatics"}, {"key": "3163_CR48", "doi-asserted-by": "publisher", "first-page": "694", "DOI": "10.2144/000112297", "volume": "41", "author": "PY Zeng", "year": "2006", "unstructured": "Zeng PY, Vakoc CR, Chen ZC, Blobel GA, Berger SL: In vivo dual cross-linking for identification of indirect DNA-associated proteins by chromatin immunoprecipitation. Biotechniques. 2006, 41: 694-10.2144/000112297. 696, 698", "journal-title": "Biotechniques"}, {"key": "3163_CR49", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1186/1471-213X-6-1", "volume": "6", "author": "V Link", "year": "2006", "unstructured": "Link V, Shevchenko A, Heisenberg CP: Proteomics of early zebrafish embryos. BMC Dev Biol. 2006, 6: 1-10.1186/1471-213X-6-1.", "journal-title": "BMC Dev Biol"}], "container-title": ["BMC Genomics"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/1471-2164-12-24.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1186/1471-2164-12-24/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1186/1471-2164-12-24.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 8]], "date-time": "2019-06-08T11:59:44Z", "timestamp": 1559995184000}, "score": 27.897623, "issued": {"date-parts": [[2011, 1, 12]]}, "references-count": 49, "journal-issue": {"published-print": {"date-parts": [[2011, 12]]}, "issue": "1"}, "alternative-id": ["3163"], "URL": "http://dx.doi.org/10.1186/1471-2164-12-24", "relation": {"cites": []}, "ISSN": ["1471-2164"], "issn-type": [{"value": "1471-2164", "type": "electronic"}], "article-number": "24"}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T16:14:03Z", "timestamp": 1574352843546}, "reference-count": 27, "publisher": "Informa UK Limited", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia & Lymphoma"], "published-print": {"date-parts": [[2008, 1]]}, "DOI": "10.1080/10428190801950058", "type": "journal-article", "created": {"date-parts": [[2008, 2, 22]], "date-time": "2008-02-22T19:53:54Z", "timestamp": 1203710034000}, "page": "385-387", "source": "Crossref", "is-referenced-by-count": 9, "title": ["The potential of histone deacetylase inhibitors for the treatment of multiple myeloma"], "prefix": "10.1080", "volume": "49", "author": [{"given": "H.", "family": "Miles Prince", "sequence": "first", "affiliation": []}, {"given": "Mark", "family": "Bishton", "sequence": "additional", "affiliation": []}, {"given": "Simon", "family": "Harrison", "sequence": "additional", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2009, 7]]}, "reference": [{"key": "CIT0001", "DOI": "10.1038/nrd2133", "doi-asserted-by": "publisher"}, {"key": "CIT0002", "DOI": "10.1200/JCO.2005.16.600", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1586/14737140.7.10.1439", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "DOI": "10.1073/pnas.180316197", "doi-asserted-by": "publisher"}, {"key": "CIT0005", "DOI": "10.1586/14737140.7.4.583", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "DOI": "10.1002/jcb.20615", "doi-asserted-by": "publisher"}, {"key": "CIT0007", "DOI": "10.1517/13543784.16.5.659", "doi-asserted-by": "publisher"}, {"key": "CIT0008", "DOI": "10.1111/j.1365-2141.2004.04882.x", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1002/ajh.1174", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "DOI": "10.1182/blood-2002-11-3514", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "DOI": "10.1182/blood-2003-01-0233", "doi-asserted-by": "publisher"}, {"key": "CIT0012", "DOI": "10.1158/0008-5472.CAN-05-4186", "doi-asserted-by": "publisher"}, {"key": "CIT0013", "author": "Piekarz R L", "volume": "108", "first-page": "2479", "year": "2006", "journal-title": "Blood (Suppl.)"}, {"key": "CIT0014", "DOI": "10.1080/10428190701817258", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "author": "Niesvizky R", "volume": "106", "first-page": "2574", "year": "2005", "journal-title": "Blood (Suppl.)"}, {"key": "CIT0016", "DOI": "10.1038/sj.leu.2404860", "doi-asserted-by": "publisher"}, {"key": "CIT0017", "author": "Galli M", "volume": "110", "first-page": "1175", "year": "2007", "journal-title": "Blood (Suppl.)"}, {"key": "CIT0018", "author": "Spencer A", "volume": "110", "first-page": "907", "year": "2007", "journal-title": "Blood (Suppl.)"}, {"key": "CIT0019", "DOI": "10.1158/1078-0432.CCR-03-0561", "doi-asserted-by": "publisher"}, {"key": "CIT0020", "DOI": "10.1182/blood-2006-04-016055", "doi-asserted-by": "publisher"}, {"key": "CIT0021", "DOI": "10.1159/000089471", "doi-asserted-by": "publisher"}, {"key": "CIT0022", "DOI": "10.1016/S0092-8674(03)00939-5", "doi-asserted-by": "publisher"}, {"key": "CIT0023", "author": "Prince M", "volume": "110", "first-page": "1167", "year": "2007", "journal-title": "Blood (Suppl.)"}, {"key": "CIT0024", "author": "Badros A", "volume": "110", "first-page": "1168", "year": "2007", "journal-title": "Blood (Suppl.)"}, {"key": "CIT0025", "author": "Weber D M", "volume": "110", "first-page": "1172", "year": "2007", "journal-title": "Blood (Suppl.)"}, {"key": "CIT0026", "author": "Campbell R A", "volume": "110", "first-page": "2520", "year": "2007", "journal-title": "Blood (Suppl.)"}, {"key": "CIT0027", "author": "Ocio E M", "volume": "110", "first-page": "1514", "year": "2007", "journal-title": "Blood (Suppl.)"}], "container-title": ["Leukemia & Lymphoma"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1080/10428190801950058", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 15]], "date-time": "2016-12-15T15:58:09Z", "timestamp": 1481817489000}, "score": 27.57403, "issued": {"date-parts": [[2008, 1]]}, "references-count": 27, "journal-issue": {"published-online": {"date-parts": [[2009, 7]]}, "published-print": {"date-parts": [[2008, 1]]}, "issue": "3"}, "alternative-id": ["10.1080/10428190801950058"], "URL": "http://dx.doi.org/10.1080/10428190801950058", "relation": {"cites": []}, "ISSN": ["1042-8194", "1029-2403"], "issn-type": [{"value": "1042-8194", "type": "print"}, {"value": "1029-2403", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T19:28:01Z", "timestamp": 1574882881450}, "reference-count": 74, "publisher": "Wiley", "issue": "1", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2018, 11, 26]], "date-time": "2018-11-26T00:00:00Z", "timestamp": 1543190400000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://creativecommons.org/licenses/by/4.0/", "start": {"date-parts": [[2018, 11, 26]], "date-time": "2018-11-26T00:00:00Z", "timestamp": 1543190400000}, "delay-in-days": 0, "content-version": "vor"}], "funder": [{"DOI": "10.13039/501100000265", "name": "Medical Research Council", "doi-asserted-by": "publisher", "award": []}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["J. Neurochem."], "published-print": {"date-parts": [[2019, 1]]}, "DOI": "10.1111/jnc.14599", "type": "journal-article", "created": {"date-parts": [[2018, 9, 30]], "date-time": "2018-09-30T11:40:15Z", "timestamp": 1538307615000}, "page": "136-156", "source": "Crossref", "is-referenced-by-count": 4, "title": ["The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease"], "prefix": "10.1111", "volume": "148", "author": [{"ORCID": "http://orcid.org/0000-0003-1250-4911", "authenticated-orcid": false, "given": "Ian F.", "family": "Harrison", "sequence": "first", "affiliation": [{"name": "UCL Centre for Advanced Biomedical Imaging; Division of Medicine; University College London; London UK"}, {"name": "Parkinson's Disease Research Group; Division of Brain Sciences; Department of Medicine; Centre for Neuroinflammation and Neurodegeneration; Imperial College London; London UK"}]}, {"given": "Nicholas M.", "family": "Powell", "sequence": "additional", "affiliation": [{"name": "UCL Centre for Advanced Biomedical Imaging; Division of Medicine; University College London; London UK"}, {"name": "Translational Imaging Group; Centre for Medical Image Computing; University College London; London UK"}]}, {"given": "David T.", "family": "Dexter", "sequence": "additional", "affiliation": [{"name": "Parkinson's Disease Research Group; Division of Brain Sciences; Department of Medicine; Centre for Neuroinflammation and Neurodegeneration; Imperial College London; London UK"}]}], "member": "311", "published-online": {"date-parts": [[2018, 11, 26]]}, "reference": [{"key": "10.1111/jnc.14599-BIB0001|jnc14599-cit-0001", "doi-asserted-by": "crossref", "first-page": "159", "DOI": "10.1016/j.brainres.2006.02.097", "article-title": "Protective role of heat shock and heat shock protein 70 in lactacystin-induced cell death both in the rat substantia nigra and PC12 cells", "volume": "1087", "author": "Ahn", "year": "2006", "journal-title": "Brain Res."}, {"key": "10.1111/jnc.14599-BIB0002|jnc14599-cit-0002", "doi-asserted-by": "crossref", "first-page": "3174", "DOI": "10.1111/j.1460-9568.2006.05192.x", "article-title": "Neuroprotection in Parkinson models varies with toxin administration protocol", "volume": "24", "author": "Anderson", "year": "2006", "journal-title": "Eur. J. Neurosci."}, {"key": "10.1111/jnc.14599-BIB0003|jnc14599-cit-0003", "doi-asserted-by": "crossref", "first-page": "610", "DOI": "10.1111/j.1460-9568.2008.06356.x", "article-title": "Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism", "volume": "28", "author": "Anderson", "year": "2008", "journal-title": "Eur. J. Neurosci."}, {"key": "10.1111/jnc.14599-BIB0004|jnc14599-cit-0004", "doi-asserted-by": "crossref", "first-page": "4963", "DOI": "10.1242/jcs.113662", "article-title": "PGC1\u03b1 and mitochondrial metabolism - emerging concepts and relevance in ageing and neurodegenerative disorders", "volume": "125", "author": "Austin", "year": "2012", "journal-title": "J. Cell Sci."}, {"key": "10.1111/jnc.14599-BIB0005|jnc14599-cit-0005", "doi-asserted-by": "crossref", "first-page": "855", "DOI": "10.1016/j.molcel.2005.02.022", "article-title": "Mechanism of sirtuin inhibition by nicotinamide: altering the NAD+ cosubstrate specificity of a Sir2 enzyme", "volume": "17", "author": "Avalos", "year": "2005", "journal-title": "Mol. Cell"}, {"key": "10.1111/jnc.14599-BIB0006|jnc14599-cit-0006", "doi-asserted-by": "crossref", "first-page": "21", "DOI": "10.1016/S0304-3940(98)00881-7", "article-title": "Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats", "volume": "259", "author": "Ayoub", "year": "1999", "journal-title": "Neurosci. Lett."}, {"key": "10.1111/jnc.14599-BIB0007|jnc14599-cit-0007", "doi-asserted-by": "crossref", "first-page": "S39", "DOI": "10.1002/ana.10479", "article-title": "Bioenergetic approaches for neuroprotection in Parkinson's disease", "volume": "53", "author": "Beal", "year": "2003", "journal-title": "Ann. Neurol."}, {"key": "10.1111/jnc.14599-BIB0008|jnc14599-cit-0008", "first-page": "289", "article-title": "Controlling the false discovery rate: a practical and powerful approach to multiple testing", "volume": "57", "author": "Benjamini", "year": "1995", "journal-title": "J. Royal Stat. Soc. Ser. B"}, {"key": "10.1111/jnc.14599-BIB0009|jnc14599-cit-0009", "doi-asserted-by": "crossref", "first-page": "68", "DOI": "10.3389/fnbeh.2015.00068", "article-title": "Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated \u03b1-synuclein", "volume": "9", "author": "Bentea", "year": "2015", "journal-title": "Front. Behav. Neurosci."}, {"key": "10.1111/jnc.14599-BIB0010|jnc14599-cit-0010", "doi-asserted-by": "crossref", "first-page": "e519", "DOI": "10.1038/cddis.2013.9", "article-title": "HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses", "volume": "4", "author": "Bolden", "year": "2013", "journal-title": "Cell Death Dis."}, {"key": "10.1111/jnc.14599-BIB0011|jnc14599-cit-0011", "doi-asserted-by": "crossref", "first-page": "275", "DOI": "10.1016/0006-8993(91)90835-J", "article-title": "Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior", "volume": "553", "author": "Carman", "year": "1991", "journal-title": "Brain Res."}, {"key": "10.1111/jnc.14599-BIB0012|jnc14599-cit-0012", "doi-asserted-by": "crossref", "first-page": "e0116919", "DOI": "10.1371/journal.pone.0116919", "article-title": "The Sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia", "volume": "10", "author": "Chen", "year": "2015", "journal-title": "PLoS ONE"}, {"key": "10.1111/jnc.14599-BIB0013|jnc14599-cit-0013", "doi-asserted-by": "crossref", "first-page": "769", "DOI": "10.1016/j.neuroimage.2010.07.039", "article-title": "Magnetic resonance virtual histology for embryos: 3D atlases for automated high-throughput phenotyping", "volume": "54", "author": "Cleary", "year": "2011", "journal-title": "NeuroImage"}, {"key": "10.1111/jnc.14599-BIB0014|jnc14599-cit-0014", "doi-asserted-by": "crossref", "first-page": "8340", "DOI": "10.1021/jm500777s", "article-title": "Discovery of potent and selective Sirtuin 2 (SIRT2) inhibitors using a fragment-based approach", "volume": "57", "author": "Cui", "year": "2014", "journal-title": "J. Med. Chem."}, {"key": "10.1111/jnc.14599-BIB0015|jnc14599-cit-0015", "doi-asserted-by": "crossref", "first-page": "583", "DOI": "10.1007/s00702-005-0353-x", "article-title": "Effects of anaesthetics on the loss of nigrostriatal dopaminergic neurons by 6-hydroxydopamine in rats", "volume": "113", "author": "Datla", "year": "2006", "journal-title": "J. Neural. Transm."}, {"key": "10.1111/jnc.14599-BIB0016|jnc14599-cit-0016", "doi-asserted-by": "crossref", "first-page": "132", "DOI": "10.1016/j.freeradbiomed.2013.01.018", "article-title": "Parkinson disease: from pathology to molecular disease mechanisms", "volume": "62", "author": "Dexter", "year": "2013", "journal-title": "Free Radic. Biol. Med."}, {"key": "10.1111/jnc.14599-BIB0017|jnc14599-cit-0017", "doi-asserted-by": "crossref", "first-page": "69", "DOI": "10.1002/cmdc.201402431", "article-title": "The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in\u00a0vitro Parkinson's disease model", "volume": "10", "author": "Di Fruscia", "year": "2015", "journal-title": "ChemMedChem"}, {"key": "10.1111/jnc.14599-BIB0018|jnc14599-cit-0018", "doi-asserted-by": "crossref", "first-page": "1008", "DOI": "10.1038/nn.3460", "article-title": "SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons", "volume": "16", "author": "Dobbin", "year": "2013", "journal-title": "Nat. Neurosci."}, {"key": "10.1111/jnc.14599-BIB0019|jnc14599-cit-0019", "doi-asserted-by": "crossref", "first-page": "494", "DOI": "10.1016/j.tips.2012.05.007", "article-title": "The neurobiology of sirtuins and their role in neurodegeneration", "volume": "33", "author": "Donmez", "year": "2012", "journal-title": "Trends Pharmacol. Sci."}, {"key": "10.1111/jnc.14599-BIB0020|jnc14599-cit-0020", "doi-asserted-by": "crossref", "first-page": "344", "DOI": "10.1002/emmm.201302451", "article-title": "SIRT1 and SIRT2: emerging targets in neurodegeneration", "volume": "5", "author": "Donmez", "year": "2013", "journal-title": "EMBO Mol. Med."}, {"key": "10.1111/jnc.14599-BIB0021|jnc14599-cit-0021", "doi-asserted-by": "crossref", "first-page": "124", "DOI": "10.1523/JNEUROSCI.3442-11.2012", "article-title": "SIRT1 protects against \u03b1-synuclein aggregation by activating molecular chaperones", "volume": "32", "author": "Donmez", "year": "2012", "journal-title": "J. Neurosci."}, {"key": "10.1111/jnc.14599-BIB0022|jnc14599-cit-0022", "doi-asserted-by": "crossref", "first-page": "225", "DOI": "10.1016/0167-8140(95)01581-Z", "article-title": "Nicotinamide pharmacokinetics in patients", "volume": "36", "author": "Dragovic", "year": "1995", "journal-title": "Radiother. Oncol."}, {"key": "10.1111/jnc.14599-BIB0023|jnc14599-cit-0023", "doi-asserted-by": "crossref", "first-page": "2316", "DOI": "10.1016/j.neurobiolaging.2014.04.029", "article-title": "Histone deacetylase 6 regulates cytotoxic \u03b1-synuclein accumulation through induction of the heat shock response", "volume": "35", "author": "Du", "year": "2014", "journal-title": "Neurobiol. Aging"}, {"key": "10.1111/jnc.14599-BIB0024|jnc14599-cit-0024", "doi-asserted-by": "crossref", "first-page": "893", "DOI": "10.1007/s00401-012-1027-z", "article-title": "Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study", "volume": "124", "author": "Durrenberger", "year": "2012", "journal-title": "Acta Neuropathol."}, {"key": "10.1111/jnc.14599-BIB0025|jnc14599-cit-0025", "doi-asserted-by": "crossref", "first-page": "8955", "DOI": "10.1523/JNEUROSCI.23-26-08955.2003", "article-title": "Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition", "volume": "23", "author": "Fornai", "year": "2003", "journal-title": "J. Neurosci."}, {"key": "10.1111/jnc.14599-BIB0026|jnc14599-cit-0026", "doi-asserted-by": "crossref", "first-page": "e677", "DOI": "10.1038/cddis.2013.205", "article-title": "A proapoptotic effect of valproic acid on progenitors of embryonic stem cell-derived glutamatergic neurons", "volume": "4", "author": "Fujiki", "year": "2013", "journal-title": "Cell Death Dis."}, {"key": "10.1111/jnc.14599-BIB0027|jnc14599-cit-0027", "doi-asserted-by": "crossref", "first-page": "529", "DOI": "10.1021/cb700160d", "article-title": "Linking SIRT2 to Parkinson's disease", "volume": "2", "author": "Garske", "year": "2007", "journal-title": "ACS Chem. Biol."}, {"key": "10.1111/jnc.14599-BIB0028|jnc14599-cit-0028", "doi-asserted-by": "crossref", "first-page": "11500", "DOI": "10.1523/JNEUROSCI.3203-08.2008", "article-title": "Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau", "volume": "28", "author": "Green", "year": "2008", "journal-title": "J. Neurosci."}, {"key": "10.1111/jnc.14599-BIB0029|jnc14599-cit-0029", "doi-asserted-by": "crossref", "first-page": "34", "DOI": "10.1016/j.pharmthera.2013.05.010", "article-title": "Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?", "volume": "140", "author": "Harrison", "year": "2013", "journal-title": "Pharmacol. Ther."}, {"key": "10.1111/jnc.14599-BIB0030|jnc14599-cit-0030", "doi-asserted-by": "crossref", "first-page": "4200", "DOI": "10.1111/bph.13208", "article-title": "Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and upregulation of neurotrophic factors", "volume": "172", "author": "Harrison", "year": "2015", "journal-title": "Br. J. Pharmacol."}, {"key": "10.1111/jnc.14599-BIB0031|jnc14599-cit-0031", "doi-asserted-by": "crossref", "first-page": "16", "DOI": "10.1016/j.neulet.2015.12.052", "article-title": "Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate", "volume": "614", "author": "Harrison", "year": "2016", "journal-title": "Neurosci. Lett."}, {"key": "10.1111/jnc.14599-BIB0032|jnc14599-cit-0032", "doi-asserted-by": "crossref", "first-page": "48", "DOI": "10.1016/j.neulet.2017.12.037", "article-title": "Pathological histone acetylation in Parkinson's disease: neuroprotection and inhibition of microglial activation through SIRT 2 inhibition", "volume": "666", "author": "Harrison", "year": "2018", "journal-title": "Neurosci. Lett."}, {"key": "10.1111/jnc.14599-BIB0033|jnc14599-cit-0033", "doi-asserted-by": "crossref", "first-page": "43", "DOI": "10.1016/j.nbd.2010.08.017", "article-title": "Nicotinamide improves motor deficits and upregulates PGC-1\u03b1 and BDNF gene expression in a mouse model of Huntington's disease", "volume": "41", "author": "Hathorn", "year": "2011", "journal-title": "Neurobiol. Dis."}, {"key": "10.1111/jnc.14599-BIB0034|jnc14599-cit-0034", "first-page": "128", "article-title": "Induction of apoptosis and acetylation of histone H3 and H4 by arctigenin in the human melanoma cell line SK-MEL-28", "volume": "2", "author": "Jeong", "year": "2011", "journal-title": "Food Nutr. Sci."}, {"key": "10.1111/jnc.14599-BIB0035|jnc14599-cit-0035", "doi-asserted-by": "crossref", "first-page": "e1000412", "DOI": "10.1371/journal.pbio.1000412", "article-title": "Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research", "volume": "8", "author": "Kilkenny", "year": "2010", "journal-title": "PLoS Biol."}, {"key": "10.1111/jnc.14599-BIB0036|jnc14599-cit-0036", "doi-asserted-by": "crossref", "first-page": "3012", "DOI": "10.1093/hmg/ddl243", "article-title": "\u03b1-Synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity", "volume": "15", "author": "Kontopoulos", "year": "2006", "journal-title": "Hum. Mol. Genet."}, {"key": "10.1111/jnc.14599-BIB0037|jnc14599-cit-0037", "doi-asserted-by": "crossref", "first-page": "30515", "DOI": "10.1074/jbc.M113.489716", "article-title": "SIRT1 protein, by blocking the activities of transcription factors FoxO1 and Fox O3, inhibits muscle atrophy and promotes muscle growth", "volume": "288", "author": "Lee", "year": "2013", "journal-title": "J. Biol. Chem."}, {"key": "10.1111/jnc.14599-BIB0038|jnc14599-cit-0038", "doi-asserted-by": "crossref", "first-page": "28", "DOI": "10.1007/s12017-009-8058-1", "article-title": "Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons", "volume": "11", "author": "Liu", "year": "2009", "journal-title": "NeuroMol. Med."}, {"key": "10.1111/jnc.14599-BIB0039|jnc14599-cit-0039", "doi-asserted-by": "crossref", "first-page": "32307", "DOI": "10.1074/jbc.C112.403048", "article-title": "Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein", "volume": "287", "author": "Liu", "year": "2012", "journal-title": "J. Biol. Chem."}, {"key": "10.1111/jnc.14599-BIB0040|jnc14599-cit-0040", "doi-asserted-by": "crossref", "first-page": "14672", "DOI": "10.1074/jbc.A112.403048", "article-title": "Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein", "volume": "288", "author": "Liu", "year": "2013", "journal-title": "J. Biol. Chem."}, {"key": "10.1111/jnc.14599-BIB0041|jnc14599-cit-0041", "doi-asserted-by": "crossref", "first-page": "402", "DOI": "10.1006/meth.2001.1262", "article-title": "Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method", "volume": "25", "author": "Livak", "year": "2001", "journal-title": "Methods"}, {"key": "10.1111/jnc.14599-BIB0042|jnc14599-cit-0042", "doi-asserted-by": "crossref", "first-page": "839", "DOI": "10.1016/j.neuint.2011.03.013", "article-title": "Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats", "volume": "58", "author": "Lorenc-Koci", "year": "2011", "journal-title": "Neurochem. Int."}, {"key": "10.1111/jnc.14599-BIB0043|jnc14599-cit-0043", "doi-asserted-by": "crossref", "first-page": "1437", "DOI": "10.1097/00001756-200208070-00018", "article-title": "Proteasome inhibition causes nigral degeneration with inclusion bodies in rats", "volume": "13", "author": "McNaught", "year": "2002", "journal-title": "NeuroReport"}, {"key": "10.1111/jnc.14599-BIB0044|jnc14599-cit-0044", "doi-asserted-by": "crossref", "first-page": "540", "DOI": "10.1073/pnas.2536759100", "article-title": "Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications", "volume": "101", "author": "Mitsiades", "year": "2004", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "10.1111/jnc.14599-BIB0045|jnc14599-cit-0045", "doi-asserted-by": "crossref", "first-page": "93", "DOI": "10.1016/j.neulet.2005.01.024", "article-title": "Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition", "volume": "380", "author": "Miwa", "year": "2005", "journal-title": "Neurosci. Lett."}, {"key": "10.1111/jnc.14599-BIB0046|jnc14599-cit-0046", "author": "Modat", "volume": "7359", "first-page": "79", "year": "2012", "volume-title": "Biomedical Image Registration", "DOI": "10.1007/978-3-642-31340-0_9", "doi-asserted-by": "crossref"}, {"key": "10.1111/jnc.14599-BIB0047|jnc14599-cit-0047", "doi-asserted-by": "crossref", "first-page": "024003", "DOI": "10.1117/1.JMI.1.2.024003", "article-title": "Global image registration using a symmetric block-matching approach", "volume": "1", "author": "Modat", "year": "2014", "journal-title": "J. Med. Imaging (Bellingham)"}, {"key": "10.1111/jnc.14599-BIB0048|jnc14599-cit-0048", "doi-asserted-by": "crossref", "first-page": "1679", "DOI": "10.1161/01.STR.31.7.1679", "article-title": "Delayed treatment with nicotinamide (vitamin B3) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats", "volume": "31", "author": "Mokudai", "year": "2000", "journal-title": "Stroke"}, {"key": "10.1111/jnc.14599-BIB0049|jnc14599-cit-0049", "doi-asserted-by": "crossref", "first-page": "95", "DOI": "10.2174/1874467210902010095", "article-title": "Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection", "volume": "2", "author": "Monti", "year": "2009", "journal-title": "Curr. Mol. Pharmacol."}, {"key": "10.1111/jnc.14599-BIB0050|jnc14599-cit-0050", "doi-asserted-by": "crossref", "first-page": "69", "DOI": "10.1159/000202972", "article-title": "Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition", "volume": "87", "author": "Niu", "year": "2009", "journal-title": "Stereotact. Funct. Neurosurg."}, {"key": "10.1111/jnc.14599-BIB0051|jnc14599-cit-0051", "doi-asserted-by": "crossref", "first-page": "143", "DOI": "10.1109/42.836373", "article-title": "New variants of a method of MRI scale standardization", "volume": "19", "author": "Nyul", "year": "2000", "journal-title": "IEEE Trans. Med. Imaging"}, {"key": "10.1111/jnc.14599-BIB0052|jnc14599-cit-0052", "doi-asserted-by": "crossref", "first-page": "516", "DOI": "10.1126/science.1143780", "article-title": "Sirtuin 2 inhibitors rescue \u03b1-synuclein-mediated toxicity in models of Parkinson's disease", "volume": "317", "author": "Outeiro", "year": "2007", "journal-title": "Science"}, {"key": "10.1111/jnc.14599-BIB0053|jnc14599-cit-0053", "author": "Paxinos", "year": "2009", "edition": "6", "volume-title": "The Rat Brain in Stereotaxic Coordinates"}, {"key": "10.1111/jnc.14599-BIB0054|jnc14599-cit-0054", "doi-asserted-by": "crossref", "first-page": "844", "DOI": "10.1158/1535-7163.MCT-09-0971", "article-title": "SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2", "volume": "9", "author": "Peck", "year": "2010", "journal-title": "Mol. Cancer Ther."}, {"key": "10.1111/jnc.14599-BIB0055|jnc14599-cit-0055", "doi-asserted-by": "crossref", "first-page": "e4090", "DOI": "10.1371/journal.pone.0004090", "article-title": "Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity", "volume": "3", "author": "Pfister", "year": "2008", "journal-title": "PLoS ONE"}, {"key": "10.1111/jnc.14599-BIB0056|jnc14599-cit-0056", "doi-asserted-by": "crossref", "first-page": "479", "DOI": "10.1007/s00429-013-0669-5", "article-title": "An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson's disease", "volume": "220", "author": "Pienaar", "year": "2015", "journal-title": "Brain Struct. Funct."}, {"key": "10.1111/jnc.14599-BIB0057|jnc14599-cit-0057", "doi-asserted-by": "crossref", "first-page": "6537", "DOI": "10.1093/emboj/cdg615", "article-title": "Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration", "volume": "22", "author": "Rouaux", "year": "2003", "journal-title": "EMBO J."}, {"key": "10.1111/jnc.14599-BIB0058|jnc14599-cit-0058", "doi-asserted-by": "crossref", "first-page": "777", "DOI": "10.1016/S0028-3908(00)00005-8", "article-title": "CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury", "volume": "39", "author": "Schallert", "year": "2000", "journal-title": "Neuropharmacology"}, {"key": "10.1111/jnc.14599-BIB0059|jnc14599-cit-0059", "first-page": "11", "article-title": "Targeting histone deacetylases: a novel approach in Parkinson's disease", "volume": "2015", "author": "Sharma", "year": "2015", "journal-title": "Parkinsons Dis."}, {"key": "10.1111/jnc.14599-BIB0060|jnc14599-cit-0060", "doi-asserted-by": "crossref", "first-page": "46", "DOI": "10.1186/s12868-017-0364-1", "article-title": "SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson's disease", "volume": "18", "author": "Singh", "year": "2017", "journal-title": "BMC Neurosci."}, {"key": "10.1111/jnc.14599-BIB0061|jnc14599-cit-0061", "doi-asserted-by": "crossref", "first-page": "621", "DOI": "10.1124/mol.109.062174", "article-title": "Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration", "volume": "77", "author": "Song", "year": "2010", "journal-title": "Mol. Pharmacol."}, {"key": "10.1111/jnc.14599-BIB0062|jnc14599-cit-0062", "doi-asserted-by": "crossref", "first-page": "27", "DOI": "10.1007/BF00971360", "article-title": "Niacinamide transport through the blood-brain barrier", "volume": "12", "author": "Spector", "year": "1987", "journal-title": "Neurochem. Res."}, {"key": "10.1111/jnc.14599-BIB0063|jnc14599-cit-0063", "doi-asserted-by": "crossref", "first-page": "1928", "DOI": "10.1021/acs.jmedchem.6b01690", "article-title": "Thienopyrimidinone based Sirtuin-2 (SIRT2)-selective inhibitors bind in the ligand induced selectivity pocket", "volume": "60", "author": "Sundriyal", "year": "2017", "journal-title": "J. Med. Chem."}, {"key": "10.1111/jnc.14599-BIB0064|jnc14599-cit-0064", "doi-asserted-by": "crossref", "first-page": "407", "DOI": "10.1046/j.1471-4159.2003.02004.x", "article-title": "Regulation of microglial inflammatory response by histone deacetylase inhibitors", "volume": "87", "author": "Suuronen", "year": "2003", "journal-title": "J. Neurochem."}, {"key": "10.1111/jnc.14599-BIB0065|jnc14599-cit-0065", "doi-asserted-by": "crossref", "first-page": "1871", "DOI": "10.1016/j.bmcl.2014.03.026", "article-title": "Identification of novel SIRT2-selective inhibitors using a click chemistry approach", "volume": "24", "author": "Tatum", "year": "2014", "journal-title": "Bioorg. Med. Chem. Lett."}, {"key": "10.1111/jnc.14599-BIB0066|jnc14599-cit-0066", "doi-asserted-by": "crossref", "first-page": "1310", "DOI": "10.1109/TMI.2010.2046908", "article-title": "N4ITK: improved N3 bias correction", "volume": "29", "author": "Tustison", "year": "2010", "journal-title": "IEEE Trans. Med. Imaging"}, {"key": "10.1111/jnc.14599-BIB0067|jnc14599-cit-0067", "doi-asserted-by": "crossref", "first-page": "485", "DOI": "10.1016/0006-8993(70)90187-3", "article-title": "Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system", "volume": "24", "author": "Ungerstedt", "year": "1970", "journal-title": "Brain Res."}, {"key": "10.1111/jnc.14599-BIB0068|jnc14599-cit-0068", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1186/1471-2202-11-1", "article-title": "Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease", "volume": "11", "author": "Vernon", "year": "2010", "journal-title": "BMC Neurosci."}, {"key": "10.1111/jnc.14599-BIB0069|jnc14599-cit-0069", "doi-asserted-by": "crossref", "first-page": "e17269", "DOI": "10.1371/journal.pone.0017269", "article-title": "Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease", "volume": "6", "author": "Vernon", "year": "2011", "journal-title": "PLoS ONE"}, {"key": "10.1111/jnc.14599-BIB0070|jnc14599-cit-0070", "doi-asserted-by": "crossref", "first-page": "482", "DOI": "10.1002/ar.1092310411", "article-title": "Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator", "volume": "231", "author": "West", "year": "1991", "journal-title": "Anat. Rec."}, {"key": "10.1111/jnc.14599-BIB0071|jnc14599-cit-0071", "doi-asserted-by": "crossref", "first-page": "188", "DOI": "10.1111/j.1471-4159.2010.06914.x", "article-title": "Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease", "volume": "115", "author": "Xie", "year": "2010", "journal-title": "J. Neurochem."}, {"key": "10.1111/jnc.14599-BIB0072|jnc14599-cit-0072", "doi-asserted-by": "crossref", "first-page": "5541", "DOI": "10.1038/sj.onc.1210620", "article-title": "Histone deacetylase inhibitors: molecular mechanisms of action", "volume": "26", "author": "Xu", "year": "2007", "journal-title": "Oncogene"}, {"key": "10.1111/jnc.14599-BIB0073|jnc14599-cit-0073", "doi-asserted-by": "crossref", "first-page": "1116", "DOI": "10.1016/j.neuroimage.2006.01.015", "article-title": "User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability", "volume": "31", "author": "Yushkevich", "year": "2006", "journal-title": "NeuroImage"}, {"key": "10.1111/jnc.14599-BIB0074|jnc14599-cit-0074", "doi-asserted-by": "crossref", "first-page": "52ra73", "DOI": "10.1126/scitranslmed.3001059", "article-title": "PGC-1\u03b1, a potential therapeutic target for early intervention in Parkinson's disease", "volume": "2", "author": "Zheng", "year": "2010", "journal-title": "Sci. Transl. Med."}], "container-title": ["Journal of Neurochemistry"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjnc.14599", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://onlinelibrary.wiley.com/wol1/doi/10.1111/jnc.14599/fullpdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 1, 15]], "date-time": "2019-01-15T16:32:08Z", "timestamp": 1547569928000}, "score": 25.634464, "issued": {"date-parts": [[2018, 11, 26]]}, "references-count": 74, "journal-issue": {"published-print": {"date-parts": [[2019, 1]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.1111/jnc.14599", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0022-3042"], "issn-type": [{"value": "0022-3042", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T22:11:16Z", "timestamp": 1574460676627}, "reference-count": 1, "publisher": "Springer Science and Business Media LLC", "issue": "9", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2010, 9, 1]], "date-time": "2010-09-01T00:00:00Z", "timestamp": 1283299200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Drug Discov"], "published-print": {"date-parts": [[2010, 9]]}, "DOI": "10.1038/nrd3261", "type": "journal-article", "created": {"date-parts": [[2010, 9, 2]], "date-time": "2010-09-02T03:35:23Z", "timestamp": 1283398523000}, "page": "681-681", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Targeting histone acetylation"], "prefix": "10.1038", "volume": "9", "author": [{"given": "Charlotte", "family": "Harrison", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "BFnrd3261_CR1", "doi-asserted-by": "publisher", "first-page": "774", "DOI": "10.1038/nm.2175", "volume": "16", "author": "H Wurtele", "year": "2010", "unstructured": "Wurtele, H. et al. Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy. Nature Med. 16, 774\u2013780 (2010)", "journal-title": "Nature Med."}], "container-title": ["Nature Reviews Drug Discovery"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrd3261.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd3261", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd3261.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 19]], "date-time": "2019-04-19T18:46:31Z", "timestamp": 1555699591000}, "score": 25.206734, "issued": {"date-parts": [[2010, 9]]}, "references-count": 1, "journal-issue": {"published-print": {"date-parts": [[2010, 9]]}, "issue": "9"}, "alternative-id": ["BFnrd3261"], "URL": "http://dx.doi.org/10.1038/nrd3261", "relation": {"cites": []}, "ISSN": ["1474-1776", "1474-1784"], "issn-type": [{"value": "1474-1776", "type": "print"}, {"value": "1474-1784", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T03:57:32Z", "timestamp": 1574308652819}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2009, 7, 1]], "date-time": "2009-07-01T00:00:00Z", "timestamp": 1246406400000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "https://www.elsevier.com/open-access/userlicense/1.0/", "start": {"date-parts": [[2013, 10, 3]], "date-time": "2013-10-03T00:00:00Z", "timestamp": 1380758400000}, "delay-in-days": 1555, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Developmental Biology"], "published-print": {"date-parts": [[2009, 7]]}, "DOI": "10.1016/j.ydbio.2009.05.082", "type": "journal-article", "created": {"date-parts": [[2009, 6, 26]], "date-time": "2009-06-26T13:15:24Z", "timestamp": 1246022124000}, "page": "408", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Neurodevelopmental functions of the epigenetic machinery in the zebrafish embryo: Histone Deacetylase 1 regulates transformation of neural progenitors into neurons and glia"], "prefix": "10.1016", "volume": "331", "author": [{"given": "Michael R.", "family": "Harrison", "sequence": "first", "affiliation": []}, {"given": "Aristophanes S.", "family": "Georgiou", "sequence": "additional", "affiliation": []}, {"given": "Elewys G.", "family": "Lightman", "sequence": "additional", "affiliation": []}, {"given": "Adam J.", "family": "Buckle", "sequence": "additional", "affiliation": []}, {"given": "Herman P.", "family": "Spaink", "sequence": "additional", "affiliation": []}, {"given": "Vincent T.", "family": "Cunliffe", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Developmental Biology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0012160609003856?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0012160609003856?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 18]], "date-time": "2018-12-18T20:25:12Z", "timestamp": 1545164712000}, "score": 22.344608, "issued": {"date-parts": [[2009, 7]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2009, 7]]}, "issue": "2"}, "alternative-id": ["S0012160609003856"], "URL": "http://dx.doi.org/10.1016/j.ydbio.2009.05.082", "ISSN": ["0012-1606"], "issn-type": [{"value": "0012-1606", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T11:23:53Z", "timestamp": 1574767433628}, "reference-count": 93, "publisher": "Informa Healthcare", "issue": "4", "content-domain": {"domain": ["www.tandfonline.com"], "crossmark-restriction": true}, "short-container-title": ["Expert Opinion on Orphan Drugs"], "published-print": {"date-parts": [[2016, 4, 2]]}, "DOI": "10.1517/21678707.2016.1149467", "type": "journal-article", "created": {"date-parts": [[2016, 2, 20]], "date-time": "2016-02-20T16:26:32Z", "timestamp": 1455985592000}, "page": "417-427", "update-policy": "http://dx.doi.org/10.1080/tandf_crossmark_01", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Histone deacetylase inhibitors in myeloproliferative neoplasms: current roles and future prospects"], "prefix": "10.1517", "volume": "4", "author": [{"given": "A", "family": "Tedjaseputra", "sequence": "first", "affiliation": []}, {"given": "S", "family": "Galli", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Ibrahim", "sequence": "additional", "affiliation": []}, {"given": "CN", "family": "Harrison", "sequence": "additional", "affiliation": []}, {"given": "DP", "family": "McLornan", "sequence": "additional", "affiliation": []}], "member": "3197", "published-online": {"date-parts": [[2016, 2, 24]]}, "reference": [{"key": "CIT0001", "author": "Swerdlow S", "year": "2008", "edition": "4", "volume-title": "WHO classification of tumours of haematopoietic and lymphoid tissues"}, {"key": "CIT0002", "DOI": "10.1038/nature03546", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1056/NEJMoa051113", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "DOI": "10.1016/S0140-6736(05)74230-6", "doi-asserted-by": "publisher"}, {"key": "CIT0005", "DOI": "10.1182/asheducation-2011.1.208", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "DOI": "10.1056/NEJMoa1311347", "doi-asserted-by": "publisher"}, {"key": "CIT0007", "DOI": "10.1371/journal.pmed.0030270", "doi-asserted-by": "publisher"}, {"key": "CIT0008", "DOI": "10.1056/NEJMoa1312542", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1182/blood-2014-06-583161", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "DOI": "10.1007/s13148-011-0050-6", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "DOI": "10.1182/blood-2014-05-577635", "doi-asserted-by": "publisher"}, {"key": "CIT0012", "DOI": "10.1038/leu.2009.47", "doi-asserted-by": "publisher"}, {"key": "CIT0013", "DOI": "10.1056/NEJMoa0810069", "doi-asserted-by": "publisher"}, {"key": "CIT0014", "DOI": "10.1182/blood-2008-12-194548", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "DOI": "10.1038/nature08240", "doi-asserted-by": "publisher"}, {"key": "CIT0016", "DOI": "10.1038/ng.621", "doi-asserted-by": "publisher"}, {"key": "CIT0017", "DOI": "10.1038/leu.2011.82", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "DOI": "10.1038/leu.2009.141", "doi-asserted-by": "publisher"}, {"key": "CIT0019", "DOI": "10.1111/j.1365-2141.2012.09179.x", "doi-asserted-by": "publisher"}, {"key": "CIT0020", "DOI": "10.1111/j.1365-2141.2005.05535.x", "doi-asserted-by": "publisher"}, {"key": "CIT0021", "DOI": "10.1111/j.1365-2141.2010.08122.x", "doi-asserted-by": "publisher"}, {"key": "CIT0022", "DOI": "10.1200/JCO.2010.31.8436", "doi-asserted-by": "publisher"}, {"key": "CIT0023", "DOI": "10.1056/NEJMoa1208500", "doi-asserted-by": "publisher"}, {"key": "CIT0024", "DOI": "10.1056/NEJMoa1409002", "doi-asserted-by": "publisher"}, {"key": "CIT0025", "DOI": "10.1111/bjh.13605", "doi-asserted-by": "publisher"}, {"key": "CIT0026", "DOI": "10.1056/NEJMoa043800", "doi-asserted-by": "publisher"}, {"key": "CIT0027", "DOI": "10.1177/2040620710394474", "doi-asserted-by": "publisher"}, {"key": "CIT0028", "DOI": "10.1182/blood-2011-10-387787", "doi-asserted-by": "publisher"}, {"key": "CIT0029", "DOI": "10.1056/NEJMoa1503479", "doi-asserted-by": "publisher"}, {"issue": "4", "key": "CIT0030", "first-page": "446", "volume": "150", "author": "Rambaldi A", "year": "2010", "journal-title": "Br J Haematol"}, {"key": "CIT0031", "DOI": "10.1111/bjh.12416", "doi-asserted-by": "publisher"}, {"key": "CIT0032", "DOI": "10.1056/NEJMoa1110557", "doi-asserted-by": "publisher"}, {"key": "CIT0033", "DOI": "10.1056/NEJMoa1110556", "doi-asserted-by": "publisher"}, {"key": "CIT0034", "DOI": "10.3324/haematol.2014.119545", "doi-asserted-by": "publisher"}, {"key": "CIT0035", "DOI": "10.1182/blood-2013-02-484832", "doi-asserted-by": "publisher"}, {"key": "CIT0036", "DOI": "10.1182/blood-2009-09-245837", "doi-asserted-by": "publisher"}, {"key": "CIT0037", "DOI": "10.1182/blood-2008-07-170449", "doi-asserted-by": "publisher"}, {"key": "CIT0038", "DOI": "10.1182/asheducation-2013.1.545", "doi-asserted-by": "publisher"}, {"key": "CIT0039", "DOI": "10.1172/JCI42442", "doi-asserted-by": "publisher"}, {"key": "CIT0040", "DOI": "10.1158/1535-7163.MCT-12-0862", "doi-asserted-by": "publisher"}, {"key": "CIT0041", "DOI": "10.18632/oncotarget.1951", "doi-asserted-by": "publisher"}, {"key": "CIT0043", "DOI": "10.1126/science.184.4139.868", "doi-asserted-by": "publisher"}, {"key": "CIT0044", "DOI": "10.1016/j.cell.2007.01.033", "doi-asserted-by": "publisher"}, {"key": "CIT0045", "DOI": "10.1016/j.cell.2007.02.005", "doi-asserted-by": "publisher"}, {"key": "CIT0046", "author": "Ververis K", "volume": "7", "first-page": "47", "year": "2013", "journal-title": "Biologics"}, {"key": "CIT0047", "DOI": "10.1016/j.molonc.2012.07.003", "doi-asserted-by": "publisher"}, {"key": "CIT0048", "DOI": "10.3390/molecules20033898", "doi-asserted-by": "publisher"}, {"key": "CIT0049", "DOI": "10.1517/14728221003796609", "doi-asserted-by": "publisher"}, {"key": "CIT0050", "DOI": "10.1111/j.1365-2141.2010.08301.x", "doi-asserted-by": "publisher"}, {"key": "CIT0051", "DOI": "10.3109/10428194.2011.597905", "doi-asserted-by": "publisher"}, {"key": "CIT0052", "DOI": "10.1038/sj.onc.1207674", "doi-asserted-by": "publisher"}, {"key": "CIT0053", "DOI": "10.1080/10428190802527699", "doi-asserted-by": "publisher"}, {"key": "CIT0054", "DOI": "10.1038/nature08448", "doi-asserted-by": "publisher"}, {"key": "CIT0055", "DOI": "10.1038/nrd4360", "doi-asserted-by": "publisher"}, {"key": "CIT0056", "DOI": "10.1126/science.1175371", "doi-asserted-by": "publisher"}, {"key": "CIT0057", "DOI": "10.1038/nrd2133", "doi-asserted-by": "publisher"}, {"key": "CIT0058", "DOI": "10.1038/nm1161", "doi-asserted-by": "publisher"}, {"key": "CIT0059", "DOI": "10.1182/blood-2013-03-488114", "doi-asserted-by": "publisher"}, {"key": "CIT0060", "DOI": "10.1054/bjoc.2000.1327", "doi-asserted-by": "publisher"}, {"key": "CIT0061", "DOI": "10.1091/mbc.11.6.2069", "doi-asserted-by": "publisher"}, {"key": "CIT0062", "DOI": "10.1146/annurev-immunol-032712-100008", "doi-asserted-by": "publisher"}, {"key": "CIT0063", "DOI": "10.1158/0008-5472.CAN-07-5270", "doi-asserted-by": "publisher"}, {"key": "CIT0064", "DOI": "10.1007/s00280-011-1766-x", "doi-asserted-by": "publisher"}, {"key": "CIT0065", "DOI": "10.1038/sj.leu.2404478", "doi-asserted-by": "publisher"}, {"key": "CIT0066", "DOI": "10.1172/JCI69738", "doi-asserted-by": "publisher"}, {"key": "CIT0068", "DOI": "10.1016/j.leukres.2012.03.003", "doi-asserted-by": "publisher"}, {"key": "CIT0069", "DOI": "10.1111/bjh.12332", "doi-asserted-by": "publisher"}, {"key": "CIT0070", "DOI": "10.1158/1078-0432.CCR-07-1461", "doi-asserted-by": "publisher"}, {"issue": "7", "key": "CIT0071", "first-page": "2781", "volume": "109", "author": "Gojo I", "year": "2007", "journal-title": "Blood"}, {"key": "CIT0072", "DOI": "10.1016/S1470-2045(11)70265-0", "doi-asserted-by": "publisher"}, {"key": "CIT0073", "DOI": "10.1182/blood-2011-10-387365", "doi-asserted-by": "publisher"}, {"key": "CIT0074", "DOI": "10.1158/1078-0432.CCR-12-0055", "doi-asserted-by": "publisher"}, {"key": "CIT0075", "DOI": "10.1002/ijc.23694", "doi-asserted-by": "publisher"}, {"key": "CIT0076", "DOI": "10.3324/haematol.2013.084160", "doi-asserted-by": "publisher"}, {"key": "CIT0077", "DOI": "10.1016/j.bcmd.2007.01.003", "doi-asserted-by": "publisher"}, {"key": "CIT0078", "DOI": "10.1634/stemcells.2008-0377", "doi-asserted-by": "publisher"}, {"key": "CIT0079", "DOI": "10.1158/0008-5472.CAN-07-0572", "doi-asserted-by": "publisher"}, {"key": "CIT0080", "DOI": "10.1016/j.ccr.2010.12.020", "doi-asserted-by": "publisher"}, {"key": "CIT0081", "DOI": "10.1084/jem.20110540", "doi-asserted-by": "publisher"}, {"key": "CIT0082", "DOI": "10.1016/j.exphem.2012.04.007", "doi-asserted-by": "publisher"}, {"key": "CIT0083", "DOI": "10.1016/j.exphem.2012.10.013", "doi-asserted-by": "publisher"}, {"key": "CIT0084", "DOI": "10.1182/blood-2009-05-222133", "doi-asserted-by": "publisher"}, {"key": "CIT0085", "DOI": "10.1158/1078-0432.CCR-13-0905", "doi-asserted-by": "publisher"}, {"key": "CIT0086", "DOI": "10.1182/blood-2011-02-336743", "doi-asserted-by": "publisher"}, {"key": "CIT0089", "DOI": "10.1016/j.leukres.2015.01.009", "doi-asserted-by": "publisher"}, {"key": "CIT0090", "DOI": "10.1182/blood-2006-03-009746", "doi-asserted-by": "publisher"}, {"key": "CIT0091", "DOI": "10.1111/bjh.12220", "doi-asserted-by": "publisher"}, {"key": "CIT0092", "DOI": "10.1111/bjh.12384", "doi-asserted-by": "publisher"}, {"key": "CIT0095", "DOI": "10.1182/blood-2013-11-536557", "doi-asserted-by": "publisher"}, {"key": "CIT0096", "DOI": "10.1038/leu.2014.57", "doi-asserted-by": "publisher"}, {"key": "CIT0097", "DOI": "10.1056/NEJMoa1412098", "doi-asserted-by": "publisher"}, {"key": "CIT0098", "DOI": "10.3324/haematol.2013.095109", "doi-asserted-by": "publisher"}, {"key": "CIT0101", "DOI": "10.1056/NEJMoa1310523", "doi-asserted-by": "publisher"}], "container-title": ["Expert Opinion on Orphan Drugs"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1517/21678707.2016.1149467", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 13]], "date-time": "2016-12-13T13:46:01Z", "timestamp": 1481636761000}, "score": 21.74651, "issued": {"date-parts": [[2016, 2, 24]]}, "references-count": 93, "journal-issue": {"published-online": {"date-parts": [[2016, 2, 29]]}, "published-print": {"date-parts": [[2016, 4, 2]]}, "issue": "4"}, "alternative-id": ["10.1517/21678707.2016.1149467"], "URL": "http://dx.doi.org/10.1517/21678707.2016.1149467", "relation": {"cites": []}, "ISSN": ["2167-8707"], "issn-type": [{"value": "2167-8707", "type": "electronic"}], "assertion": [{"value": "The publishing and review policy for this title is described in its Aims & Scope.", "order": 1, "name": "peerreview_statement", "label": "Peer Review Statement"}, {"value": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ieod20", "URL": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ieod20", "order": 2, "name": "aims_and_scope_url", "label": "Aim & Scope"}]}, {"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T13:43:32Z", "timestamp": 1576849412859}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "12", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2009, 6, 15]]}, "DOI": "10.1158/1078-0432.ccr-08-2785", "type": "journal-article", "created": {"date-parts": [[2009, 6, 15]], "date-time": "2009-06-15T07:44:00Z", "timestamp": 1245051840000}, "page": "3958-3969", "source": "Crossref", "is-referenced-by-count": 225, "title": ["Clinical Studies of Histone Deacetylase Inhibitors"], "prefix": "10.1158", "volume": "15", "author": [{"given": "H. M.", "family": "Prince", "sequence": "first", "affiliation": []}, {"given": "M. J.", "family": "Bishton", "sequence": "additional", "affiliation": []}, {"given": "S. J.", "family": "Harrison", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2009, 6, 9]]}, "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-08-2785", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T12:03:19Z", "timestamp": 1482494599000}, "score": 21.74651, "issued": {"date-parts": [[2009, 6, 9]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2009, 6, 15]]}, "published-print": {"date-parts": [[2009, 6, 15]]}, "issue": "12"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-08-2785", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T07:11:25Z", "timestamp": 1575443485781}, "reference-count": 1, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2014, 2, 28]], "date-time": "2014-02-28T00:00:00Z", "timestamp": 1393545600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Drug Discov"], "published-print": {"date-parts": [[2014, 3]]}, "DOI": "10.1038/nrd4270", "type": "journal-article", "created": {"date-parts": [[2014, 2, 28]], "date-time": "2014-02-28T05:34:40Z", "timestamp": 1393565680000}, "page": "178-178", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Targeting neuronal loss in Gaucher's disease"], "prefix": "10.1038", "volume": "13", "author": [{"given": "Charlotte", "family": "Harrison", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2014, 2, 28]]}, "reference": [{"key": "BFnrd4270_CR1", "doi-asserted-by": "publisher", "first-page": "204", "DOI": "10.1038/nm.3449", "volume": "20", "author": "EB Vitner", "year": "2014", "unstructured": "Vitner, E. B. et al. RIPK3 as a potential therapeutic target for Gaucher's disease. Nature Med. 20, 204\u2013208 (2014)", "journal-title": "Nature Med."}], "container-title": ["Nature Reviews Drug Discovery"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrd4270.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd4270", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd4270.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 20]], "date-time": "2019-04-20T13:40:45Z", "timestamp": 1555767645000}, "score": 21.31105, "issued": {"date-parts": [[2014, 2, 28]]}, "references-count": 1, "journal-issue": {"published-print": {"date-parts": [[2014, 3]]}, "issue": "3"}, "alternative-id": ["BFnrd4270"], "URL": "http://dx.doi.org/10.1038/nrd4270", "relation": {"cites": []}, "ISSN": ["1474-1776", "1474-1784"], "issn-type": [{"value": "1474-1776", "type": "print"}, {"value": "1474-1784", "type": "electronic"}], "subject": ["Pharmacology", "Drug Discovery", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T18:41:54Z", "timestamp": 1574793714392}, "reference-count": 24, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1981, 7, 1]], "date-time": "1981-07-01T00:00:00Z", "timestamp": 362793600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Fertility and Sterility"], "published-print": {"date-parts": [[1981, 7]]}, "DOI": "10.1016/s0015-0282(16)45621-9", "type": "journal-article", "created": {"date-parts": [[2016, 5, 6]], "date-time": "2016-05-06T15:46:26Z", "timestamp": 1462549586000}, "page": "71-75", "source": "Crossref", "is-referenced-by-count": 17, "title": ["The Diagnostic and Therapeutic Potential of the Postcoital Test"], "prefix": "10.1016", "volume": "36", "author": [{"given": "Robert F.", "family": "Harrison", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Fertility and Sterility"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0015028216456219?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0015028216456219?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 12]], "date-time": "2018-09-12T10:24:58Z", "timestamp": 1536747898000}, "score": 20.762175, "issued": {"date-parts": [[1981, 7]]}, "references-count": 24, "journal-issue": {"published-print": {"date-parts": [[1981, 7]]}, "issue": "1"}, "alternative-id": ["S0015028216456219"], "URL": "http://dx.doi.org/10.1016/s0015-0282(16)45621-9", "ISSN": ["0015-0282"], "issn-type": [{"value": "0015-0282", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T06:09:55Z", "timestamp": 1574489395840}, "reference-count": 42, "publisher": "American Society of Hematology", "issue": "1", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2010, 12, 4]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>The seminal discovery of the JAK2V617F mutation, which is highly prevalent in Philadelphia-negative myeloproliferative disorders, now renamed neoplasms, triggered an almost unprecedented explosion of interest and data in the field. Descriptions of additional mutations in exon 12 of JAK2, at position 515 in MPL, and a number of other mutations at low frequency followed these discoveries. These advances in our understanding of molecular pathogenesis of these conditions coincided with the publication of results from two major clinical studies, ECLAP and PT-1, which contributed important clinical insights and facilitated significant correlative data collection. This article, focusing mainly upon essential thrombocythemia and polycythemia vera, reviews four major themes: the impact upon classification of these disorders considering a radical review of current terminology, and then three areas pertinent to clinical management: the indications for cytoreductive therapy in which the key targets are to reduce thrombohemorrhagic complications, relieve disease-related symptoms, and minimize the risk of transformation to secondary myeloid malignancy such as myelodysplasia, leukemia, and secondary myelofibrosis; and second reviewing current and, last, future therapeutic options, in particular interferon and JAK2 inhibitors.</jats:p>", "DOI": "10.1182/asheducation-2010.1.129", "type": "journal-article", "created": {"date-parts": [[2011, 1, 16]], "date-time": "2011-01-16T19:08:48Z", "timestamp": 1295204928000}, "page": "129-134", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 13, "title": ["Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera"], "prefix": "10.1182", "volume": "2010", "author": [{"given": "Claire", "family": "Harrison", "sequence": "first", "affiliation": [{"name": "Guy's and St. Thomas' National Health Service Foundation Trust, London, United Kingdom"}]}], "member": "234", "reference": [{"key": "2019111716593406000_B1", "doi-asserted-by": "crossref", "first-page": "372", "DOI": "10.1182/blood.V6.4.372.372", "article-title": "Some speculations on the myeloproliferative syndromes", "volume": "6", "author": "Dameshek", "year": "1951", "journal-title": "Blood"}, {"key": "2019111716593406000_B2", "doi-asserted-by": "crossref", "first-page": "2292", "DOI": "10.1182/blood-2002-04-1199", "article-title": "The World Health Organization (WHO) classification of the myeloid neoplasms", "volume": "100", "author": "Vardiman", "year": "2002", "journal-title": "Blood"}, {"key": "2019111716593406000_B3", "doi-asserted-by": "crossref", "first-page": "60", "DOI": "10.1182/blood-2007-05-091850", "article-title": "Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes", "volume": "111", "author": "Wilkins", "year": "2008", "journal-title": "Blood"}, {"key": "2019111716593406000_B4", "first-page": "1126", "article-title": "Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis", "volume": "85", "author": "Thiele", "year": "2000", "journal-title": "Haematologica"}, {"key": "2019111716593406000_B5", "doi-asserted-by": "crossref", "first-page": "683", "DOI": "10.1111/j.1365-2141.2006.06348.x", "article-title": "Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time", "volume": "135", "author": "Lasho", "year": "2006", "journal-title": "Br J Haematol"}, {"key": "2019111716593406000_B6", "doi-asserted-by": "crossref", "first-page": "2003", "DOI": "10.1182/blood-2009-09-245381", "article-title": "Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms", "volume": "115", "author": "Schaub", "year": "2010", "journal-title": "Blood"}, {"key": "2019111716593406000_B7", "doi-asserted-by": "crossref", "first-page": "904", "DOI": "10.1111/j.1365-2141.2008.07560.x", "article-title": "Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones", "volume": "144", "author": "Beer", "year": "2009", "journal-title": "Br J Haematol"}, {"key": "2019111716593406000_B8", "author": "Campbell", "first-page": "201", "year": "2005", "article-title": "Management of polycythemia vera and essential thrombocythemia", "journal-title": "Hematology Am Soc Hematol Educ Program", "DOI": "10.1182/asheducation-2005.1.201", "doi-asserted-by": "crossref"}, {"key": "2019111716593406000_B9", "doi-asserted-by": "crossref", "first-page": "1945", "DOI": "10.1016/S0140-6736(05)67785-9", "article-title": "Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study", "volume": "366", "author": "Campbell", "year": "2005", "journal-title": "Lancet"}, {"key": "2019111716593406000_B10", "doi-asserted-by": "crossref", "first-page": "1016", "DOI": "10.1016/j.exphem.2009.06.006", "article-title": "JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera", "volume": "37", "author": "Carobbio", "year": "2009", "journal-title": "Exp Hematol"}, {"key": "2019111716593406000_B11", "doi-asserted-by": "crossref", "first-page": "67", "DOI": "10.1016/j.leukres.2008.06.006", "article-title": "Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia", "volume": "33", "author": "Dahabreh", "year": "2008", "journal-title": "Leuk Res"}, {"key": "2019111716593406000_B12", "doi-asserted-by": "crossref", "first-page": "2199", "DOI": "10.1182/blood-2008-03-143602", "article-title": "Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden", "volume": "112", "author": "Landgren", "year": "2008", "journal-title": "Blood"}, {"key": "2019111716593406000_B13", "doi-asserted-by": "crossref", "first-page": "446", "DOI": "10.1038/ng.334", "article-title": "JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms", "volume": "41", "author": "Jones", "year": "2009", "journal-title": "Nat Genet"}, {"key": "2019111716593406000_B14", "doi-asserted-by": "crossref", "first-page": "455", "DOI": "10.1038/ng.342", "article-title": "A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms", "volume": "41", "author": "Kilpivaara", "year": "2009", "journal-title": "Nat Genet"}, {"key": "2019111716593406000_B15", "doi-asserted-by": "crossref", "first-page": "450", "DOI": "10.1038/ng.341", "article-title": "A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms", "volume": "41", "author": "Olcaydu", "year": "2009", "journal-title": "Nat Genet"}, {"key": "2019111716593406000_B16", "doi-asserted-by": "crossref", "first-page": "4517", "DOI": "10.1182/blood-2009-08-236448", "article-title": "The JAK2 46/1 haplotype predisposes to MPL mutated myeloproliferative neoplasms", "volume": "115", "author": "Jones", "year": "2010", "journal-title": "Blood"}, {"key": "2019111716593406000_B17", "doi-asserted-by": "crossref", "first-page": "2435", "DOI": "10.1182/blood-2006-04-018259", "article-title": "Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia", "volume": "108", "author": "Scott", "year": "2006", "journal-title": "Blood"}, {"key": "2019111716593406000_B18", "doi-asserted-by": "crossref", "first-page": "3913", "DOI": "10.1182/blood-2006-03-008805", "article-title": "Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression", "volume": "108", "author": "Moliterno", "year": "2006", "journal-title": "Blood"}, {"key": "2019111716593406000_B19", "doi-asserted-by": "crossref", "first-page": "3931", "DOI": "10.1182/blood-2007-08-107748", "article-title": "Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice", "volume": "111", "author": "Tiedt", "year": "2008", "journal-title": "Blood"}, {"key": "2019111716593406000_B20", "doi-asserted-by": "crossref", "first-page": "459", "DOI": "10.1056/NEJMoa065202", "article-title": "JAK2 exon 12 Mutations in polycythemia vera and idiopathic erythrocytosis", "volume": "356", "author": "Scott", "year": "2007", "journal-title": "N Engl J Med"}, {"key": "2019111716593406000_B21", "doi-asserted-by": "crossref", "first-page": "1732", "DOI": "10.1634/stemcells.2007-0899", "article-title": "Downregulation of signal transducer and activator of transcription 5 (STAT5) in CD34+ cells promotes megakaryocytic development, whereas activation of STAT5 drives erythropoiesis", "volume": "26", "author": "Olthof", "year": "2008", "journal-title": "Stem Cells"}, {"key": "2019111716593406000_B22", "doi-asserted-by": "crossref", "first-page": "840", "DOI": "10.1182/blood-2006-12-064287", "article-title": "Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia", "volume": "110", "author": "Vannucchi", "year": "2007", "journal-title": "Blood"}, {"key": "2019111716593406000_B23", "doi-asserted-by": "crossref", "first-page": "1952", "DOI": "10.1038/sj.leu.2404854", "article-title": "Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden", "volume": "21", "author": "Vannucchi", "year": "2007", "journal-title": "Leukemia"}, {"key": "2019111716593406000_B24", "doi-asserted-by": "crossref", "first-page": "437", "DOI": "10.1038/sj.leu.2404914", "article-title": "Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment", "volume": "22", "author": "Barosi", "year": "2008", "journal-title": "Leukemia"}, {"key": "2019111716593406000_B25", "doi-asserted-by": "crossref", "first-page": "2891", "DOI": "10.1182/blood-2009-08-236596", "article-title": "Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm", "volume": "115", "author": "Beer", "year": "2010", "journal-title": "Blood"}, {"key": "2019111716593406000_B26", "doi-asserted-by": "crossref", "first-page": "1402", "DOI": "10.1182/blood-2008-01-134114", "article-title": "JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders", "volume": "112", "author": "Plo", "year": "2008", "journal-title": "Blood"}, {"key": "2019111716593406000_B27", "doi-asserted-by": "crossref", "first-page": "2778", "DOI": "10.1056/NEJMoa0804953", "article-title": "Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders", "volume": "359", "author": "Zhao", "year": "2008", "journal-title": "N Engl J Med"}, {"key": "2019111716593406000_B28", "doi-asserted-by": "crossref", "first-page": "352", "DOI": "10.1111/j.1365-2141.2010.08122.x", "article-title": "Guideline for investigation and management of adults and children presenting with a thrombocytosis", "volume": "149", "author": "Harrison", "year": "2010", "journal-title": "Br J Haematol"}, {"key": "2019111716593406000_B29", "doi-asserted-by": "crossref", "first-page": "33", "DOI": "10.1056/NEJMoa043800", "article-title": "Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia", "volume": "353", "author": "Harrison", "year": "2005", "journal-title": "N Engl J Med"}, {"key": "2019111716593406000_B30", "doi-asserted-by": "crossref", "first-page": "3135", "DOI": "10.1182/blood-2008-04-153783", "article-title": "Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia", "volume": "112", "author": "Carobbio", "year": "2008", "journal-title": "Blood"}, {"key": "2019111716593406000_B31", "doi-asserted-by": "crossref", "first-page": "4829", "DOI": "10.1182/blood-2008-09-176818", "article-title": "Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference", "volume": "113", "author": "Barosi", "year": "2009", "journal-title": "Blood"}, {"key": "2019111716593406000_B32", "doi-asserted-by": "crossref", "first-page": "277", "DOI": "10.1038/sj.leu.2404473", "article-title": "A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group", "volume": "21", "author": "Barosi", "year": "2007", "journal-title": "Leukemia"}, {"key": "2019111716593406000_B33", "doi-asserted-by": "crossref", "first-page": "403", "DOI": "10.1016/S0140-6736(88)92881-4", "article-title": "Recombinant interferon-alpha for treatment of polycythaemia vera", "volume": "2", "author": "Silver", "year": "1988", "journal-title": "Lancet"}, {"key": "2019111716593406000_B34", "doi-asserted-by": "crossref", "first-page": "3339", "DOI": "10.1182/blood-2005-09-3917", "article-title": "Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha", "volume": "107", "author": "Jones", "year": "2006", "journal-title": "Blood"}, {"key": "2019111716593406000_B35", "doi-asserted-by": "crossref", "first-page": "2012", "DOI": "10.1002/cncr.23018", "article-title": "PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study", "volume": "110", "author": "Jabbour", "year": "2007", "journal-title": "Cancer"}, {"key": "2019111716593406000_B36", "doi-asserted-by": "crossref", "first-page": "3065", "DOI": "10.1182/blood-2008-03-143537", "article-title": "Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera", "volume": "112", "author": "Kiladjian", "year": "2008", "journal-title": "Blood"}, {"key": "2019111716593406000_B37", "doi-asserted-by": "crossref", "first-page": "5418", "DOI": "10.1200/JCO.2009.23.6075", "article-title": "Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera", "volume": "27", "author": "Quintas-Cardama", "year": "2009", "journal-title": "J Clin Oncol"}, {"key": "2019111716593406000_B38", "doi-asserted-by": "crossref", "first-page": "753", "DOI": "10.1182/blood.V114.22.753.753", "article-title": "An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: Update of 39 enrolled patients [Abstract]", "volume": "114", "author": "Moliterno", "year": "2009", "journal-title": "Blood"}, {"key": "2019111716593406000_B39", "doi-asserted-by": "crossref", "first-page": "311", "DOI": "10.1182/blood.V114.22.311.311", "article-title": "Phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. [Abstract]", "volume": "114", "author": "Verstovsek", "year": "2009", "journal-title": "Blood"}, {"key": "2019111716593406000_B40", "first-page": "100", "article-title": "A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms [Abstract]", "volume": "112", "author": "Rambaldi", "year": "2008", "journal-title": "Blood"}, {"key": "2019111716593406000_B41", "doi-asserted-by": "crossref", "first-page": "308", "DOI": "10.1182/blood.V114.22.308.308", "article-title": "A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post-PV/ET MF) [Abstract]", "volume": "114", "author": "Mascarenhas", "year": "2009", "journal-title": "Blood"}, {"key": "2019111716593406000_B42", "doi-asserted-by": "crossref", "first-page": "2991", "DOI": "10.1200/JCO.2008.20.3174", "article-title": "Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy", "volume": "27", "author": "Campbell", "year": "2009", "journal-title": "J Clin Oncol"}], "container-title": ["Hematology"], "language": "en", "link": [{"URL": "http://ashpublications.org/hematology/article-pdf/2010/1/129/1493530/bep00110000129.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/hematology/article-pdf/2010/1/129/1493530/bep00110000129.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 17]], "date-time": "2019-11-17T21:59:45Z", "timestamp": 1574027985000}, "score": 20.596844, "issued": {"date-parts": [[2010, 12, 4]]}, "references-count": 42, "journal-issue": {"published-print": {"date-parts": [[2010, 12, 4]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.1182/asheducation-2010.1.129", "relation": {"cites": []}, "ISSN": ["1520-4391", "1520-4383"], "issn-type": [{"value": "1520-4391", "type": "print"}, {"value": "1520-4383", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T06:03:13Z", "timestamp": 1574488993832}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "2", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[1993, 2, 1]], "date-time": "1993-02-01T00:00:00Z", "timestamp": 728524800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Br J Cancer"], "published-print": {"date-parts": [[1993, 2]]}, "DOI": "10.1038/bjc.1993.56", "type": "journal-article", "created": {"date-parts": [[2011, 1, 14]], "date-time": "2011-01-14T11:04:54Z", "timestamp": 1295003094000}, "page": "297-303", "source": "Crossref", "is-referenced-by-count": 38, "title": ["Therapeutic potential of analogues of amiloride: inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy"], "prefix": "10.1038", "volume": "67", "author": [{"given": "RP", "family": "Maidorn", "sequence": "first", "affiliation": []}, {"given": "EJ", "family": "Cragoe", "sequence": "additional", "affiliation": []}, {"given": "IF", "family": "Tannock", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["British Journal of Cancer"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bjc199356.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bjc199356", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bjc199356.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 16]], "date-time": "2019-03-16T20:10:38Z", "timestamp": 1552767038000}, "score": 20.577763, "issued": {"date-parts": [[1993, 2]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1993, 2]]}, "issue": "2"}, "alternative-id": ["BFbjc199356"], "URL": "http://dx.doi.org/10.1038/bjc.1993.56", "ISSN": ["0007-0920", "1532-1827"], "issn-type": [{"value": "0007-0920", "type": "print"}, {"value": "1532-1827", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:46:46Z", "timestamp": 1574135206857}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2004, 8, 1]], "date-time": "2004-08-01T00:00:00Z", "timestamp": 1091318400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Cardiac Failure"], "published-print": {"date-parts": [[2004, 8]]}, "DOI": "10.1016/j.cardfail.2004.06.153", "type": "journal-article", "created": {"date-parts": [[2004, 8, 21]], "date-time": "2004-08-21T13:11:59Z", "timestamp": 1093093919000}, "page": "S60", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Differential effects of histone deacetylase inhibitors on hypertrophic signaling pathways"], "prefix": "10.1016", "volume": "10", "author": [{"given": "Hansjorg", "family": "Rindt", "sequence": "first", "affiliation": []}, {"given": "Matthew", "family": "Dreitz", "sequence": "additional", "affiliation": []}, {"given": "Lisa", "family": "Hollingsworth", "sequence": "additional", "affiliation": []}, {"given": "David", "family": "Hood", "sequence": "additional", "affiliation": []}, {"given": "Erik", "family": "Bush", "sequence": "additional", "affiliation": []}, {"given": "Brooke", "family": "Harrison", "sequence": "additional", "affiliation": []}, {"given": "Timothy", "family": "McKinsey", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Journal of Cardiac Failure"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1071916404002878?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1071916404002878?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 4]], "date-time": "2019-02-04T20:23:51Z", "timestamp": 1549311831000}, "score": 20.45742, "issued": {"date-parts": [[2004, 8]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2004, 8]]}, "issue": "4"}, "alternative-id": ["S1071916404002878"], "URL": "http://dx.doi.org/10.1016/j.cardfail.2004.06.153", "ISSN": ["1071-9164"], "issn-type": [{"value": "1071-9164", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T21:07:19Z", "timestamp": 1574456839438}, "reference-count": 64, "publisher": "MDPI AG", "issue": "8", "license": [{"URL": "https://creativecommons.org/licenses/by/4.0/", "start": {"date-parts": [[2010, 8, 17]], "date-time": "2010-08-17T00:00:00Z", "timestamp": 1282003200000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Pharmaceuticals"], "DOI": "10.3390/ph3082674", "type": "journal-article", "created": {"date-parts": [[2010, 8, 17]], "date-time": "2010-08-17T15:36:41Z", "timestamp": 1282059401000}, "page": "2674-2688", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Overview of Histone Deacetylase Inhibitors in Haematological Malignancies"], "prefix": "10.3390", "volume": "3", "author": [{"given": "Mark J.", "family": "Bishton", "sequence": "first", "affiliation": []}, {"given": "Ricky W.", "family": "Johnstone", "sequence": "additional", "affiliation": []}, {"given": "Michael", "family": "Dickinson", "sequence": "additional", "affiliation": []}, {"given": "Simon", "family": "Harrison", "sequence": "additional", "affiliation": []}, {"given": "H. Miles", "family": "Prince", "sequence": "additional", "affiliation": []}], "member": "1968", "published-online": {"date-parts": [[2010, 8, 17]]}, "reference": [{"key": "ref1", "doi-asserted-by": "crossref", "first-page": "669", "DOI": "10.1016/j.cell.2007.01.033", "article-title": "The mammalian epigenome", "volume": "128", "author": "Bernstein", "year": "2007", "journal-title": "Cell"}, {"key": "ref2", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.1002/jcb.20179", "article-title": "Regulation of histone deacetylase activities", "volume": "93", "author": "Sengupta", "year": "2004", "journal-title": "J. Cell Biochem."}, {"key": "ref3", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.1016/j.jmb.2004.02.006", "article-title": "Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis", "volume": "338", "author": "Gregoretti", "year": "2004", "journal-title": "J. Mol. Biol."}, {"key": "ref4", "doi-asserted-by": "crossref", "first-page": "5420", "DOI": "10.1038/sj.onc.1210610", "article-title": "Histone deacetylases and cancer", "volume": "26", "author": "Glozak", "year": "2007", "journal-title": "Oncogene"}, {"key": "ref5", "doi-asserted-by": "crossref", "first-page": "258", "DOI": "10.1038/35104721", "article-title": "Code of silence", "volume": "414", "author": "Rice", "year": "2001", "journal-title": "Nature"}, {"key": "ref6", "doi-asserted-by": "crossref", "first-page": "2042", "DOI": "10.1056/NEJMra023075", "article-title": "Gene silencing in cancer in association with promoter hypermethylation", "volume": "349", "author": "Herman", "year": "2003", "journal-title": "N. Engl. J. Med."}, {"key": "ref7", "doi-asserted-by": "crossref", "first-page": "287", "DOI": "10.1038/nrd772", "article-title": "Histone-deacetylase inhibitors: novel drugs for the treatment of cancer", "volume": "1", "author": "Johnstone", "year": "2002", "journal-title": "Nat. Rev. Drug Discov."}, {"key": "ref8", "doi-asserted-by": "crossref", "first-page": "1210", "DOI": "10.1093/jnci/92.15.1210", "article-title": "Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells", "volume": "92", "author": "Marks", "year": "2000", "journal-title": "J. Natl. Cancer Inst."}, {"key": "ref9", "doi-asserted-by": "crossref", "first-page": "3971", "DOI": "10.1200/JCO.2005.16.600", "article-title": "Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies", "volume": "23", "author": "Bhalla", "year": "2005", "journal-title": "J. Clin. Oncol."}, {"key": "ref10", "doi-asserted-by": "crossref", "first-page": "981", "DOI": "10.1182/blood-2007-10-115873", "article-title": "Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia", "volume": "112", "author": "Garcia-Manero", "year": "2008", "journal-title": "Blood"}, {"key": "ref11", "first-page": "2781", "article-title": "Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias", "volume": "109", "author": "Gojo", "year": "2007", "journal-title": "Blood"}, {"key": "ref12", "doi-asserted-by": "crossref", "first-page": "2318", "DOI": "10.1158/1078-0432.CCR-06-2672", "article-title": "Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma", "volume": "13", "author": "Mann", "year": "2007", "journal-title": "Clin. Cancer Res."}, {"key": "ref13", "doi-asserted-by": "crossref", "first-page": "166", "DOI": "10.1200/JCO.2005.01.9679", "article-title": "Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies", "volume": "24", "author": "O\u2019Connor", "year": "2006", "journal-title": "J. Clin. Oncol."}, {"key": "ref14", "doi-asserted-by": "crossref", "first-page": "964", "DOI": "10.1093/annonc/mdn031", "article-title": "Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma", "volume": "19", "author": "Crump", "year": "2008", "journal-title": "Ann. Oncol."}, {"key": "ref15", "doi-asserted-by": "crossref", "first-page": "196", "DOI": "10.1111/j.1349-7006.2009.01360.x", "article-title": "Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma", "volume": "101", "author": "Watanabe", "year": "2009", "journal-title": "Cancer Sci."}, {"key": "ref16", "first-page": "1564", "article-title": "A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin\u2019s Lymphoma. A California Cancer Consortium Study", "volume": "112", "author": "Kirschbaum", "year": "2008", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref17", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1182/blood-2006-06-025999", "article-title": "Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)", "volume": "109", "author": "Duvic", "year": "2007", "journal-title": "Blood"}, {"key": "ref18", "doi-asserted-by": "crossref", "first-page": "3785", "DOI": "10.1158/0008-5472.CAN-07-6091", "article-title": "Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma", "volume": "68", "author": "Fantin", "year": "2008", "journal-title": "Cancer Res."}, {"key": "ref19", "doi-asserted-by": "crossref", "first-page": "6532", "DOI": "10.1073/pnas.0913912107", "article-title": "HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy", "volume": "107", "author": "Khan", "year": "2010", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "ref20", "doi-asserted-by": "crossref", "first-page": "1060", "DOI": "10.1182/blood-2007-06-098061", "article-title": "Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes", "volume": "111", "author": "Garcia-Manero", "year": "2008", "journal-title": "Blood"}, {"key": "ref21", "doi-asserted-by": "crossref", "first-page": "10833", "DOI": "10.1073/pnas.191208598", "article-title": "The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species", "volume": "98", "author": "Ruefli", "year": "2001", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "ref22", "first-page": "1060", "article-title": "Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial", "volume": "111", "author": "Loboda", "year": "2006", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref23", "doi-asserted-by": "crossref", "first-page": "1375", "DOI": "10.3324/haematol.2009.009217", "article-title": "A phase 2 study of vorinostat in acute myeloid leukemia", "volume": "94", "author": "Schaefer", "year": "2009", "journal-title": "Haematologica"}, {"key": "ref24", "first-page": "1055", "article-title": "Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)", "volume": "114", "author": "Garcia-Manero", "year": "2009", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref25", "doi-asserted-by": "crossref", "first-page": "385", "DOI": "10.1080/10428190801950058", "article-title": "The potential of histone deacetylase inhibitors for the treatment of multiple myeloma", "volume": "49", "author": "Prince", "year": "2008", "journal-title": "Leuk. Lymphoma"}, {"key": "ref26", "doi-asserted-by": "crossref", "first-page": "3441", "DOI": "10.1182/blood-2006-04-016055", "article-title": "Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells", "volume": "108", "author": "Catley", "year": "2006", "journal-title": "Blood"}, {"key": "ref27", "doi-asserted-by": "crossref", "first-page": "406", "DOI": "10.1182/blood-2009-07-235663", "article-title": "Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma", "volume": "116", "author": "Kikuchi", "year": "2010", "journal-title": "Blood"}, {"key": "ref28", "doi-asserted-by": "crossref", "first-page": "794", "DOI": "10.3324/haematol.2009.015495", "article-title": "In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma", "volume": "95", "author": "Ocio", "year": "2010", "journal-title": "Haematologica"}, {"key": "ref29", "doi-asserted-by": "crossref", "first-page": "5250", "DOI": "10.1158/1078-0432.CCR-08-2850", "article-title": "Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma", "volume": "15", "author": "Badros", "year": "2009", "journal-title": "Clin. Cancer Res."}, {"key": "ref30", "first-page": "4916", "article-title": "FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases", "volume": "62", "author": "Furumai", "year": "2002", "journal-title": "Cancer Res."}, {"key": "ref31", "doi-asserted-by": "crossref", "first-page": "959", "DOI": "10.1182/blood-2004-05-1693", "article-title": "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia", "volume": "105", "author": "Byrd", "year": "2005", "journal-title": "Blood"}, {"key": "ref32", "doi-asserted-by": "crossref", "first-page": "2865", "DOI": "10.1182/blood.V98.9.2865", "article-title": "Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report", "volume": "98", "author": "Piekarz", "year": "2001", "journal-title": "Blood"}, {"key": "ref33", "doi-asserted-by": "crossref", "first-page": "5410", "DOI": "10.1200/JCO.2008.21.6150", "article-title": "Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma", "volume": "27", "author": "Piekarz", "year": "2009", "journal-title": "J. Clin. Oncol."}, {"key": "ref34", "first-page": "263", "article-title": "Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study", "volume": "112", "author": "Kim", "year": "2008", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref35", "doi-asserted-by": "crossref", "first-page": "256", "DOI": "10.1111/j.1365-2141.2009.07954.x", "article-title": "Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma", "volume": "148", "author": "Bates", "year": "2010", "journal-title": "Br. J. Haematol."}, {"key": "ref36", "doi-asserted-by": "crossref", "first-page": "3189", "DOI": "10.1182/blood-2005-07-2813", "article-title": "Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy", "volume": "107", "author": "Nebozhyn", "year": "2006", "journal-title": "Blood"}, {"key": "ref37", "first-page": "1657", "article-title": "Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL)", "volume": "114", "author": "Piekarz", "year": "2009", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref38", "first-page": "3709", "article-title": "Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin", "volume": "114", "author": "Cabell", "year": "2009", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref39", "first-page": "2574", "article-title": "Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM)", "volume": "106", "author": "Niesvizky", "year": "2005", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref40", "first-page": "3698", "article-title": "High Response Rates with the Combination of Bortezomib, Dexamethasone and the Pan-Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma in a Phase I/II Clinical Trial", "volume": "112", "author": "Harrison", "year": "2008", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref41", "doi-asserted-by": "crossref", "first-page": "4628", "DOI": "10.1158/1078-0432.CCR-06-0511", "article-title": "A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies", "volume": "12", "author": "Giles", "year": "2006", "journal-title": "Clin. Cancer Res."}, {"key": "ref42", "first-page": "3500", "article-title": "Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin\u2019s lymphoma", "volume": "25", "author": "Prince", "year": "2007", "journal-title": "J. Clin. Oncol."}, {"key": "ref43", "doi-asserted-by": "crossref", "first-page": "4500", "DOI": "10.1158/1078-0432.CCR-07-4262", "article-title": "Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma", "volume": "14", "author": "Ellis", "year": "2008", "journal-title": "Clin. Cancer Res."}, {"key": "ref44", "first-page": "1005", "article-title": "Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL)", "volume": "112", "author": "Duvic", "year": "2008", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref45", "first-page": "958", "article-title": "Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies", "volume": "112", "author": "Ottmann", "year": "2008", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref46", "first-page": "2898", "article-title": "Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis", "volume": "114", "author": "DeAngelo", "year": "2009", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref47", "first-page": "308", "article-title": "A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)", "volume": "114", "author": "Mascarenhas", "year": "2009", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref48", "first-page": "2774", "article-title": "A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma", "volume": "112", "author": "Wolf", "year": "2008", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref49", "first-page": "3852", "article-title": "A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma", "volume": "114", "author": "San-Miguel", "year": "2009", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref50", "first-page": "4254", "article-title": "A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to >=2 BCR-ABL Tyrosine Kinase Inhibitors", "volume": "112", "author": "Zaritskey", "year": "2008", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref51", "first-page": "4263", "article-title": "A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to >=2 BCR-ABL Tyrosine Kinase Inhibitors", "volume": "112", "author": "Guilhot", "year": "2008", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref52", "doi-asserted-by": "crossref", "first-page": "170", "DOI": "10.1111/j.1600-0609.2008.01102.x", "article-title": "A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia", "volume": "81", "author": "Gimsing", "year": "2008", "journal-title": "Eur. J. Haematol."}, {"key": "ref53", "first-page": "3453", "article-title": "Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study", "volume": "110", "author": "Advani", "year": "2007", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref54", "first-page": "3583", "article-title": "A Phase II Study of PXD101 in Advanced Multiple Myeloma", "volume": "108", "author": "Sullivan", "year": "2006", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref55", "first-page": "8580", "article-title": "Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma", "volume": "27", "author": "Zain", "year": "2009", "journal-title": "J. Clin. Oncol."}, {"key": "ref56", "first-page": "1953", "article-title": "Interim Results of a Phase I/II Clinical Trial of Belinostat in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy", "volume": "112", "author": "Schlenk", "year": "2008", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref57", "doi-asserted-by": "crossref", "first-page": "3441", "DOI": "10.1158/1078-0432.CCR-07-4427", "article-title": "Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay", "volume": "14", "author": "Bonfils", "year": "2008", "journal-title": "Clin. Cancer Res."}, {"key": "ref58", "first-page": "444", "article-title": "Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)", "volume": "110", "author": "Garcia-Manero", "year": "2007", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref59", "doi-asserted-by": "crossref", "first-page": "8507", "DOI": "10.1200/jco.2008.26.15_suppl.8507", "article-title": "Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)", "volume": "26", "author": "Bociek", "year": "2008", "journal-title": "J. Clin. Oncol."}, {"key": "ref60", "doi-asserted-by": "crossref", "first-page": "1424", "DOI": "10.1182/blood-2008-01-133769", "article-title": "Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines", "volume": "112", "author": "Buglio", "year": "2008", "journal-title": "Blood"}, {"key": "ref61", "doi-asserted-by": "crossref", "first-page": "8528", "DOI": "10.1200/jco.2008.26.15_suppl.8528", "article-title": "Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study", "volume": "26", "author": "Crump", "year": "2008", "journal-title": "J. Clin. Oncol."}, {"key": "ref62", "doi-asserted-by": "crossref", "first-page": "507", "DOI": "10.1111/j.1365-2141.2009.07881.x", "article-title": "Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia", "volume": "147", "author": "Blum", "year": "2009", "journal-title": "Br. J. Haematol."}, {"key": "ref63", "first-page": "517", "article-title": "Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage", "volume": "108", "author": "Gore", "year": "2006", "journal-title": "ASH Ann. Meet. Abstr."}, {"key": "ref64", "doi-asserted-by": "crossref", "first-page": "2764", "DOI": "10.1182/blood-2009-02-203547", "article-title": "Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies", "volume": "114", "author": "Fandy", "year": "2009", "journal-title": "Blood"}], "container-title": ["Pharmaceuticals"], "language": "en", "link": [{"URL": "http://www.mdpi.com/1424-8247/3/8/2674/pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 3, 16]], "date-time": "2018-03-16T16:37:58Z", "timestamp": 1521218278000}, "score": 20.45742, "issued": {"date-parts": [[2010, 8, 17]]}, "references-count": 64, "journal-issue": {"published-online": {"date-parts": [[2010, 8]]}, "issue": "8"}, "alternative-id": ["ph3082674"], "URL": "http://dx.doi.org/10.3390/ph3082674", "relation": {"cites": []}, "ISSN": ["1424-8247"], "issn-type": [{"value": "1424-8247", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T21:32:57Z", "timestamp": 1574717577427}, "reference-count": 47, "publisher": "Springer Science and Business Media LLC", "issue": "8", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2015, 8, 1]], "date-time": "2015-08-01T00:00:00Z", "timestamp": 1438387200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Cancer Gene Ther"], "published-print": {"date-parts": [[2015, 8]]}, "DOI": "10.1038/cgt.2015.37", "type": "journal-article", "created": {"date-parts": [[2015, 8, 7]], "date-time": "2015-08-07T10:21:05Z", "timestamp": 1438942865000}, "page": "410-416", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 11, "title": ["Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation"], "prefix": "10.1038", "volume": "22", "author": [{"given": "S", "family": "Jang", "sequence": "first", "affiliation": []}, {"given": "X-M", "family": "Yu", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Odorico", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Clark", "sequence": "additional", "affiliation": []}, {"given": "R", "family": "Jaskula-Sztul", "sequence": "additional", "affiliation": []}, {"given": "C M", "family": "Schienebeck", "sequence": "additional", "affiliation": []}, {"given": "K R", "family": "Kupcho", "sequence": "additional", "affiliation": []}, {"given": "A D", "family": "Harrison", "sequence": "additional", "affiliation": []}, {"given": "G N", "family": "Winston-McPherson", "sequence": "additional", "affiliation": []}, {"given": "W", "family": "Tang", "sequence": "additional", "affiliation": []}, {"given": "H", "family": "Chen", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2015, 8, 7]]}, "reference": [{"key": "BFcgt201537_CR1", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.3322/caac.21208", "volume": "64", "author": "R Siegel", "year": "2014", "unstructured": "Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9\u201329.", "journal-title": "CA Cancer J Clin"}, {"key": "BFcgt201537_CR2", "doi-asserted-by": "publisher", "first-page": "1181", "DOI": "10.1002/cncr.11175", "volume": "97", "author": "J Zidan", "year": "2003", "unstructured": "Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A . Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 2003; 97: 1181\u20131185.", "journal-title": "Cancer"}, {"key": "BFcgt201537_CR3", "doi-asserted-by": "publisher", "first-page": "1148", "DOI": "10.1634/theoncologist.2014-0182", "volume": "19", "author": "KT Hsu", "year": "2014", "unstructured": "Hsu KT, Yu XM, Audhya AW, Jaume JC, Lloyd RV, Miyamoto S et al. Novel approaches in anaplastic thyroid cancer therapy. Oncologist 2014; 19: 1148\u20131155.", "journal-title": "Oncologist"}, {"key": "BFcgt201537_CR4", "doi-asserted-by": "publisher", "first-page": "113", "DOI": "10.1097/MOO.0b013e328343af3d", "volume": "19", "author": "RO Wein", "year": "2011", "unstructured": "Wein RO, Weber RS . Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg 2011; 19: 113\u2013118.", "journal-title": "Curr Opin Otolaryngol Head Neck Surg"}, {"key": "BFcgt201537_CR5", "doi-asserted-by": "publisher", "first-page": "337", "DOI": "10.1016/S0936-6555(03)00162-6", "volume": "15", "author": "D Ford", "year": "2003", "unstructured": "Ford D, Giridharan S, McConkey C, Hartley A, Brammer C, Watkinson JC et al. External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2003; 15: 337\u2013341.", "journal-title": "Clin Oncol (R Coll Radiol)"}, {"key": "BFcgt201537_CR6", "first-page": "151", "volume": "106", "author": "EL Mazzaferri", "year": "1995", "unstructured": "Mazzaferri EL, Jhiang SM . Differentiated thyroid cancer long-term impact of initial therapy. Trans Am Clin Climatol Assoc 1995; 106: 151\u2013168 discussion 168-170.", "journal-title": "Trans Am Clin Climatol Assoc"}, {"key": "BFcgt201537_CR7", "doi-asserted-by": "publisher", "first-page": "194", "DOI": "10.1038/35106079", "volume": "1", "author": "P Marks", "year": "2001", "unstructured": "Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK . Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194\u2013202.", "journal-title": "Nat Rev Cancer"}, {"key": "BFcgt201537_CR8", "doi-asserted-by": "publisher", "first-page": "150", "DOI": "10.1038/ncponc0106", "volume": "2", "author": "WK Kelly", "year": "2005", "unstructured": "Kelly WK, Marks PA . Drug insight: Histone deacetylase inhibitors\u2014development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005; 2: 150\u2013157.", "journal-title": "Nat Clin Pract Oncol"}, {"key": "BFcgt201537_CR9", "doi-asserted-by": "publisher", "first-page": "38", "DOI": "10.1038/nrc1779", "volume": "6", "author": "S Minucci", "year": "2006", "unstructured": "Minucci S, Pelicci PG . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38\u201351.", "journal-title": "Nat Rev Cancer"}, {"key": "BFcgt201537_CR10", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.2174/138920007780655397", "volume": "8", "author": "V Santini", "year": "2007", "unstructured": "Santini V, Gozzini A, Ferrari G . Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 2007; 8: 383\u2013393.", "journal-title": "Curr Drug Metab"}, {"key": "BFcgt201537_CR11", "doi-asserted-by": "publisher", "first-page": "1210", "DOI": "10.1093/jnci/92.15.1210", "volume": "92", "author": "PA Marks", "year": "2000", "unstructured": "Marks PA, Richon VM, Rifkind RA . Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92: 1210\u20131216.", "journal-title": "J Natl Cancer Inst"}, {"key": "BFcgt201537_CR12", "doi-asserted-by": "publisher", "first-page": "3958", "DOI": "10.1158/1078-0432.CCR-03-0776", "volume": "11", "author": "CS Mitsiades", "year": "2005", "unstructured": "Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A et al. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 2005; 11: 3958\u20133965.", "journal-title": "Clin Cancer Res"}, {"key": "BFcgt201537_CR13", "doi-asserted-by": "publisher", "first-page": "191", "DOI": "10.1016/j.jss.2014.02.042", "volume": "190", "author": "E Weinlander", "year": "2014", "unstructured": "Weinlander E, Somnay Y, Harrison AD, Wang C, Cheng YQ, Jaskula-Sztul R et al. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth. J Surg Res 2014; 190: 191\u2013197.", "journal-title": "J Surg Res"}, {"key": "BFcgt201537_CR14", "doi-asserted-by": "publisher", "first-page": "5570", "DOI": "10.1158/1078-0432.CCR-06-0367", "volume": "12", "author": "QT Luong", "year": "2006", "unstructured": "Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP . Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 2006; 12: 5570\u20135577.", "journal-title": "Clin Cancer Res"}, {"key": "BFcgt201537_CR15", "doi-asserted-by": "publisher", "first-page": "504", "DOI": "10.1016/j.surg.2010.10.007", "volume": "149", "author": "EJ Mitmaker", "year": "2011", "unstructured": "Mitmaker EJ, Griff NJ, Grogan RH, Sarkar R, Kebebew E, Duh QY et al. Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery 2011; 149: 504\u2013511.", "journal-title": "Surgery"}, {"key": "BFcgt201537_CR16", "doi-asserted-by": "publisher", "first-page": "E1150", "DOI": "10.1210/jc.2011-2970", "volume": "97", "author": "MG Catalano", "year": "2012", "unstructured": "Catalano MG, Fortunati N, Pugliese M, Marano F, Ortoleva L, Poli R et al. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2012; 97: E1150\u2013E1159.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "BFcgt201537_CR17", "doi-asserted-by": "publisher", "first-page": "465", "DOI": "10.1677/joe.1.06970", "volume": "191", "author": "MG Catalano", "year": "2006", "unstructured": "Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 2006; 191: 465\u2013472.", "journal-title": "J Endocrinol"}, {"key": "BFcgt201537_CR18", "doi-asserted-by": "publisher", "first-page": "2601", "DOI": "10.1016/j.bmcl.2011.01.134", "volume": "21", "author": "W Tang", "year": "2011", "unstructured": "Tang W, Luo T, Greenberg EF, Bradner JE, Schreiber SL . Discovery of histone deacetylase 8 selective inhibitors. Bioorg Med Chem Lett 2011; 21: 2601\u20132605.", "journal-title": "Bioorg Med Chem Lett"}, {"key": "BFcgt201537_CR19", "doi-asserted-by": "publisher", "first-page": "4331", "DOI": "10.1210/jc.2008-1102", "volume": "93", "author": "RE Schweppe", "year": "2008", "unstructured": "Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008; 93: 4331\u20134341.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "BFcgt201537_CR20", "doi-asserted-by": "publisher", "first-page": "66", "DOI": "10.1097/CAD.0b013e3283584f75", "volume": "24", "author": "Y Somnay", "year": "2013", "unstructured": "Somnay Y, Simon K, Harrison AD, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M . Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro. Anticancer Drugs 2013; 24: 66\u201372.", "journal-title": "Anticancer Drugs"}, {"key": "BFcgt201537_CR21", "doi-asserted-by": "publisher", "first-page": "1227", "DOI": "10.1177/1087057111416004", "volume": "16", "author": "F Halley", "year": "2011", "unstructured": "Halley F, Reinshagen J, Ellinger B, Wolf M, Niles AL, Evans NJ et al. A bioluminogenic HDAC activity assay: validation and screening. J Biomol Screen 2011; 16: 1227\u20131235.", "journal-title": "J Biomol Screen"}, {"key": "BFcgt201537_CR22", "doi-asserted-by": "publisher", "first-page": "710213", "DOI": "10.4061/2011/710213", "volume": "2011", "author": "S Kimura", "year": "2011", "unstructured": "Kimura S . Thyroid-specific transcription factors and their roles in thyroid cancer. J Thyroid Res 2011; 2011: 710213.", "journal-title": "J Thyroid Res"}, {"key": "BFcgt201537_CR23", "doi-asserted-by": "publisher", "first-page": "453", "DOI": "10.1245/ASO.2006.05.042", "volume": "13", "author": "C Are", "year": "2006", "unstructured": "Are C, Shaha AR . Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006; 13: 453\u2013464.", "journal-title": "Ann Surg Oncol"}, {"key": "BFcgt201537_CR24", "doi-asserted-by": "publisher", "first-page": "1231", "DOI": "10.2147/OTT.S46545", "volume": "9", "author": "N Denaro", "year": "2013", "unstructured": "Denaro N, Nigro CL, Russi EG, Merlano MC . The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Onco Targets Ther 2013; 9: 1231\u20131241.", "journal-title": "Onco Targets Ther"}, {"key": "BFcgt201537_CR25", "doi-asserted-by": "publisher", "first-page": "152", "DOI": "10.1007/s11912-007-0014-3", "volume": "9", "author": "WR Cornett", "year": "2007", "unstructured": "Cornett WR, Sharma AK, Day TA, Richardson MS, Hoda RS, van Heerden JA et al. Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 2007; 9: 152\u2013158.", "journal-title": "Curr Oncol Rep"}, {"key": "BFcgt201537_CR26", "doi-asserted-by": "publisher", "first-page": "525", "DOI": "10.1016/j.ecl.2008.02.003", "volume": "37", "author": "RL Neff", "year": "2008", "unstructured": "Neff RL, Farrar WB, Kloos RT, Burman KD . Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008; 37: 525\u2013538 xi.", "journal-title": "Endocrinol Metab Clin North Am"}, {"key": "BFcgt201537_CR27", "doi-asserted-by": "publisher", "first-page": "143", "DOI": "10.1093/annonc/mdp156", "volume": "20", "author": "F Pacini", "year": "2009", "unstructured": "Pacini F, Castagna MG, Brilli L, Pentheroudakis G . Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20: 143\u2013146.", "journal-title": "Ann Oncol"}, {"key": "BFcgt201537_CR28", "doi-asserted-by": "publisher", "first-page": "577", "DOI": "10.1016/S0889-8529(18)30311-6", "volume": "19", "author": "DS Cooper", "year": "1990", "unstructured": "Cooper DS, Schneyer CR . Follicular and Hurthle cell carcinoma of the thyroid. Endocrinol Metab Clin North Am 1990; 19: 577\u2013591.", "journal-title": "Endocrinol Metab Clin North Am"}, {"key": "BFcgt201537_CR29", "doi-asserted-by": "publisher", "first-page": "685", "DOI": "10.1016/S0889-8529(18)30317-7", "volume": "19", "author": "HR Maxon 3rd", "year": "1990", "unstructured": "Maxon HR 3rd, Smith HS . Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19: 685\u2013718.", "journal-title": "Endocrinol Metab Clin North Am"}, {"key": "BFcgt201537_CR30", "doi-asserted-by": "publisher", "first-page": "7320", "DOI": "10.1074/jbc.M008363200", "volume": "276", "author": "EA Slee", "year": "2001", "unstructured": "Slee EA, Adrain C, Martin SJ . Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 2001; 276: 7320\u20137326.", "journal-title": "J Biol Chem"}, {"key": "BFcgt201537_CR31", "doi-asserted-by": "publisher", "first-page": "8", "DOI": "10.1016/j.molcel.2010.06.017", "volume": "39", "author": "R Krishnakumar", "year": "2010", "unstructured": "Krishnakumar R, Kraus WL . The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39: 8\u201324.", "journal-title": "Mol Cell"}, {"key": "BFcgt201537_CR32", "doi-asserted-by": "publisher", "first-page": "259", "DOI": "10.1515/hsz-2011-0254", "volume": "393", "author": "DM Mitrea", "year": "2012", "unstructured": "Mitrea DM, Yoon MK, Ou L, Kriwacki RW . Disorder-function relationships for the cell cycle regulatory proteins p21 and p27. Biol Chem 2012; 393: 259\u2013274.", "journal-title": "Biol Chem"}, {"key": "BFcgt201537_CR33", "doi-asserted-by": "publisher", "first-page": "812", "DOI": "10.1101/gad.7.5.812", "volume": "7", "author": "V Baldin", "year": "1993", "unstructured": "Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G . Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7: 812\u2013821.", "journal-title": "Genes Dev"}, {"key": "BFcgt201537_CR34", "doi-asserted-by": "publisher", "first-page": "226", "DOI": "10.4161/cbt.72", "volume": "1", "author": "JA Diehl", "year": "2002", "unstructured": "Diehl JA . Cycling to cancer with cyclin D1. Cancer Biol Ther 2002; 1: 226\u2013231.", "journal-title": "Cancer Biol Ther"}, {"key": "BFcgt201537_CR35", "doi-asserted-by": "publisher", "first-page": "981", "DOI": "10.1158/1541-7786.MCR-07-0324", "volume": "5", "author": "M Dokmanovic", "year": "2007", "unstructured": "Dokmanovic M, Clarke C, Marks PA . Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981\u2013989.", "journal-title": "Mol Cancer Res"}, {"key": "BFcgt201537_CR36", "doi-asserted-by": "publisher", "first-page": "30", "DOI": "10.1172/JCI69738", "volume": "124", "author": "AC West", "year": "2014", "unstructured": "West AC, Johnstone RW . New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30\u201339.", "journal-title": "J Clin Invest"}, {"key": "BFcgt201537_CR37", "doi-asserted-by": "publisher", "first-page": "376", "DOI": "10.1007/s10434-000-0376-3", "volume": "7", "author": "DS Tyler", "year": "2000", "unstructured": "Tyler DS, Shaha AR, Udelsman RA, Sherman SI, Thompson NW, Moley JF et al. Thyroid cancer: 1999 update. Ann Surg Oncol 2000; 7: 376\u2013398.", "journal-title": "Ann Surg Oncol"}, {"key": "BFcgt201537_CR38", "first-page": "3430", "volume": "86", "author": "M Kitazono", "year": "2001", "unstructured": "Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86: 3430\u20133435.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "BFcgt201537_CR39", "doi-asserted-by": "publisher", "first-page": "1006", "DOI": "10.1210/jc.2003-031407", "volume": "89", "author": "N Fortunati", "year": "2004", "unstructured": "Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G . Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2004; 89: 1006\u20131009.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "BFcgt201537_CR40", "doi-asserted-by": "publisher", "first-page": "217", "DOI": "10.1530/JME-11-0063", "volume": "48", "author": "C Puppin", "year": "2012", "unstructured": "Puppin C, Passon N, Hershman JM, Filetti S, Bulotta S, Celano M et al. Cooperative effects of SAHA and VPA on NIS gene expression and proliferation of thyroid cancer cells. J Mol Endocrinol 2012; 48: 217\u2013227.", "journal-title": "J Mol Endocrinol"}, {"key": "BFcgt201537_CR41", "doi-asserted-by": "publisher", "first-page": "984", "DOI": "10.1067/msy.2002.128690", "volume": "132", "author": "R Zarnegar", "year": "2002", "unstructured": "Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 2002; 132: 984\u2013990 discussion 990.", "journal-title": "Surgery"}, {"key": "BFcgt201537_CR42", "doi-asserted-by": "publisher", "first-page": "797", "DOI": "10.1677/erc.1.01143", "volume": "13", "author": "T Kogai", "year": "2006", "unstructured": "Kogai T, Taki K, Brent GA . Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 2006; 13: 797\u2013826.", "journal-title": "Endocr Relat Cancer"}, {"key": "BFcgt201537_CR43", "doi-asserted-by": "publisher", "first-page": "2865", "DOI": "10.1210/en.2003-1258", "volume": "145", "author": "F Furuya", "year": "2004", "unstructured": "Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004; 145: 2865\u20132875.", "journal-title": "Endocrinology"}, {"key": "BFcgt201537_CR44", "doi-asserted-by": "publisher", "first-page": "245", "DOI": "10.1677/erc.1.0978", "volume": "12", "author": "M Xing", "year": "2005", "unstructured": "Xing M . BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245\u2013262.", "journal-title": "Endocr Relat Cancer"}, {"key": "BFcgt201537_CR45", "doi-asserted-by": "publisher", "first-page": "313", "DOI": "10.1016/j.ccr.2004.09.022", "volume": "6", "author": "MJ Garnett", "year": "2004", "unstructured": "Garnett MJ, Marais R . Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6: 313\u2013319.", "journal-title": "Cancer Cell"}, {"key": "BFcgt201537_CR46", "doi-asserted-by": "publisher", "first-page": "6373", "DOI": "10.1210/jc.2005-0987", "volume": "90", "author": "M Xing", "year": "2005", "unstructured": "Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373\u20136379.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "BFcgt201537_CR47", "doi-asserted-by": "publisher", "first-page": "161", "DOI": "10.1530/ERC-13-0399", "volume": "21", "author": "Z Zhang", "year": "2014", "unstructured": "Zhang Z, Liu D, Murugan AK, Liu Z, Xing M . Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer 2014; 21: 161\u2013173.", "journal-title": "Endocr Relat Cancer"}], "container-title": ["Cancer Gene Therapy"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/cgt201537.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/cgt201537", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/cgt201537.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 14]], "date-time": "2019-04-14T05:51:07Z", "timestamp": 1555221067000}, "score": 19.807995, "issued": {"date-parts": [[2015, 8]]}, "references-count": 47, "journal-issue": {"published-print": {"date-parts": [[2015, 8]]}, "issue": "8"}, "alternative-id": ["BFcgt201537"], "URL": "http://dx.doi.org/10.1038/cgt.2015.37", "relation": {"cites": []}, "ISSN": ["0929-1903", "1476-5500"], "issn-type": [{"value": "0929-1903", "type": "print"}, {"value": "1476-5500", "type": "electronic"}], "assertion": [{"value": "6 February 2015", "order": 1, "name": "received", "label": "Received", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "24 June 2015", "order": 2, "name": "revised", "label": "Revised", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "10 July 2015", "order": 3, "name": "accepted", "label": "Accepted", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "7 August 2015", "order": 4, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "The authors declare no conflict of interest.", "order": 1, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Competing interests"}}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T06:35:10Z", "timestamp": 1575527710675}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "22", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2009, 11, 20]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Abstract 2416</jats:p>\n               <jats:p>Poster Board II-393</jats:p>\n               <jats:sec>\n                  <jats:title>Introduction.</jats:title>\n                  <jats:p>Histone Deacetylase inhibitors (HDACi) are novel anti-cancer drugs with efficacy in T-cell lymphoma, myeloid malignancies and Hodgkin lymphoma. We have previously demonstrated that reversible thrombocytopenia (TCP) is a dose-limiting toxicity (Ellis et al Clin Cancer Res 2007) of HDACi which may limit broader use of these drugs especially in combination strategies. We have developed in vivo models which recapitulate this clinical scenario.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.</jats:title>\n                  <jats:p>Administration of both the pan-HDACi panobinostat and the class I HDAC-selective inhibitor romidepsin (depsipeptide) in C57BL/6 mice induces a dose-dependant reduction in platelet number, which nadir on day 5 (from \u223c1000\u00d7109/L to \u223c300\u00d7109/L). Drug cessation results in a rebound thrombocytosis (\u223c1500\u00d7109/L) with counts normalizing after a week. We have compared and contrasted these observations with a single dose of carboplatin 100mg/kg (a chemotherapeutic agent inducing TCP by megakaryocyte ablation), and daily ABT-737 75mg/kg (a BH3 mimetic causing direct platelet apoptosis).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results.</jats:title>\n                  <jats:p>In contrast to HDACi, ABT-737 caused a 60% decrease in platelet counts after 2 hours, while carboplatin-induced TCP was not seen until 7 days. Circulating platelet half life studies in HDACi treated mice showed no difference to carboplatin, in contrast to ABT-737, with a &gt;50% reduction after 2 hours. HDACi treated mice showed reductions of new reticulated platelets, using a thiazole orange uptake assay, from 6-8% to 1-2% within 24 hours. ABT-737 caused a rapid and sustained increase (6-8% to 20-30%) in reticulated platelets, and carboplatin a reduction from 6-8% to 2-3%. HDACi induced TCP with the same kinetics and nadir in BAK-/- mice as well as in mice reconstituted with Bak-/-/Bak-/- hemopoietic stem cells which are relatively insensitive to ABT-737. Bone marrow sections showed HDACi and ABT-737 to induce a significant increase in megakaryocyte number while carboplatin resulted in a significant reduction, further indicating that HDACi-induced TCP is due to a platelet production or release defect rather than myeloablation. All drugs caused an increase in thrombopoietin (TPO) levels. Our data therefore suggests HDACi impair platelet production, and not direct platelet apoptosis. These effects are likely to be induced by inhibition of HDAC's 1 and/or 2 as the effects of panobinostat are mirrored by romidepsin. We postulated that our observations are akin to those seen in immune thrombocytopenia (ITP). AMP-4 is a mouse-specific TPO-mimetic with an activating peptide structurally identical to romiplostim, an agent licensed to treat ITP. A single subcutaneous dose of AMP-4 in mice results in marked thrombocytosis peaking at 4-5 days at \u223c3000\u00d7109/L, normalizing by 9-10 days. When AMP-4 is administered to mice at initiation of (Figure 1), or during ongoing treatment with panobinostat or romidepsin, there is a clear and consistent improvement in platelet numbers to levels similar to untreated controls.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.</jats:title>\n                  <jats:p>Thus we have demonstrated for the first time that HDACi-induced TCP can be ameliorated by the use of TPO-mimetics. Such a strategy when applied in the clinic has the potential to overcome a substantial clinical limitation of HDACi-therapy. Data will be available for the effects of HDACi on murine megakaryocytes derived from embryonic fetal liver cells, and pro-platelet formation from these cells, an essential intermediary step to platelet release. We aim to define the megakarocyte cellular targets of HDACi- induced TCP in both in vivo and in vitro models, scrutinizing the effects of AMP-4 on these systems.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Disclosures:</jats:title>\n                  <jats:p>Off Label Use: panobinostat and romidepsin are both histone deactylase inhibitors, in clinical studies for haematological malignancies. niether are licensed for use in any setting currently. Prince:Gloucester Pharmaceuticals: Consultancy. Johnstone:Novartis, Merck, Gloucester: Research Funding.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v114.22.2416.2416", "type": "journal-article", "created": {"date-parts": [[2019, 10, 9]], "date-time": "2019-10-09T22:01:32Z", "timestamp": 1570658492000}, "page": "2416-2416", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Overcoming Histone Deacetylase Inhibitor Induced Thrombocytopenia Using a Thrombopoietin Mimetic."], "prefix": "10.1182", "volume": "114", "author": [{"given": "Mark J", "family": "Bishton", "sequence": "first", "affiliation": [{"name": "Department of Hematology and Clinical Oncology., Peter MacCallum Cancer Centre, East Melbourne, Australia,"}]}, {"given": "Miles", "family": "Prince", "sequence": "additional", "affiliation": [{"name": "Peter MacCallum Cancer Centre, East Melbourne, Australia,"}]}, {"given": "Simon", "family": "Harrison", "sequence": "additional", "affiliation": [{"name": "Dept. of Hematology, Peter MacCallum Cancer Center, Melbourne, Australia,"}]}, {"given": "Ben P", "family": "Martin", "sequence": "additional", "affiliation": [{"name": "Peter MacCallum Cencer Centre, Melbourne, Australia,"}]}, {"given": "Chloe\u0301", "family": "James", "sequence": "additional", "affiliation": [{"name": "Molecular Medicine, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia,"}]}, {"given": "Benjamin T.", "family": "Kile", "sequence": "additional", "affiliation": [{"name": "Molecular Medicine, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia,"}]}, {"given": "R. W", "family": "Johnstone", "sequence": "additional", "affiliation": [{"name": "Cancer Research Immunology, Peter MacCallum Cancer Centre, East Melbourne, Australia"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/114/22/2416/63706/Overcoming-Histone-Deacetylase-Inhibitor-Induced", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/114/22/2416/63706/Overcoming-Histone-Deacetylase-Inhibitor-Induced", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 16]], "date-time": "2019-11-16T05:39:52Z", "timestamp": 1573882792000}, "score": 19.723019, "issued": {"date-parts": [[2009, 11, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2009, 11, 20]]}, "issue": "22"}, "URL": "http://dx.doi.org/10.1182/blood.v114.22.2416.2416", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T11:36:32Z", "timestamp": 1574336192103}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "1???2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Drugs"], "published-print": {"date-parts": [[1974]]}, "DOI": "10.2165/00003495-197407010-00001", "type": "journal-article", "created": {"date-parts": [[2007, 12, 5]], "date-time": "2007-12-05T10:49:29Z", "timestamp": 1196851769000}, "page": "1-7", "source": "Crossref", "is-referenced-by-count": 2, "title": ["The Pharmacology and Therapeutic Use of ??-Adrenergic Receptor Blocking Drugs in Cardiovascular Disease"], "prefix": "10.1007", "volume": "7", "author": [{"given": "D. C.", "family": "Harrison", "sequence": "first", "affiliation": []}], "member": "297", "container-title": ["Drugs"], "language": "en", "deposited": {"date-parts": [[2013, 1, 20]], "date-time": "2013-01-20T14:47:48Z", "timestamp": 1358693268000}, "score": 19.70784, "subtitle": [""], "issued": {"date-parts": [[1974]]}, "references-count": 0, "journal-issue": {"issue": "1???2"}, "URL": "http://dx.doi.org/10.2165/00003495-197407010-00001", "ISSN": ["0012-6667"], "issn-type": [{"value": "0012-6667", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T06:03:23Z", "timestamp": 1574489003848}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "4", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[1994, 10, 1]], "date-time": "1994-10-01T00:00:00Z", "timestamp": 780969600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Br J Cancer"], "published-print": {"date-parts": [[1994, 10]]}, "DOI": "10.1038/bjc.1994.360", "type": "journal-article", "created": {"date-parts": [[2011, 1, 14]], "date-time": "2011-01-14T11:22:34Z", "timestamp": 1295004154000}, "page": "617-624", "source": "Crossref", "is-referenced-by-count": 17, "title": ["Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy"], "prefix": "10.1038", "volume": "70", "author": [{"given": "J", "family": "Luo", "sequence": "first", "affiliation": []}, {"given": "IF", "family": "Tannock", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["British Journal of Cancer"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bjc1994360.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bjc1994360", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bjc1994360.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 17]], "date-time": "2019-03-17T10:00:33Z", "timestamp": 1552816833000}, "score": 19.635674, "issued": {"date-parts": [[1994, 10]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1994, 10]]}, "issue": "4"}, "alternative-id": ["BFbjc1994360"], "URL": "http://dx.doi.org/10.1038/bjc.1994.360", "ISSN": ["0007-0920", "1532-1827"], "issn-type": [{"value": "0007-0920", "type": "print"}, {"value": "1532-1827", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T00:26:29Z", "timestamp": 1574123189394}, "reference-count": 22, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Pediatric Infectious Disease Journal"], "published-print": {"date-parts": [[1997, 2]]}, "DOI": "10.1097/00006454-199702001-00004", "type": "journal-article", "created": {"date-parts": [[2003, 4, 24]], "date-time": "2003-04-24T15:43:03Z", "timestamp": 1051198983000}, "page": "S12-S16", "source": "Crossref", "is-referenced-by-count": 15, "title": ["Using antibiotic concentrations in middle ear fluid to predict potential clinical efficacy"], "prefix": "10.1097", "volume": "16", "author": [{"given": "CHRISTOPHER J.", "family": "HARRISON", "sequence": "first", "affiliation": []}], "member": "276", "container-title": ["The Pediatric Infectious Disease Journal"], "language": "en", "deposited": {"date-parts": [[2018, 2, 9]], "date-time": "2018-02-09T10:48:48Z", "timestamp": 1518173328000}, "score": 18.93033, "subtitle": [""], "issued": {"date-parts": [[1997, 2]]}, "references-count": 22, "URL": "http://dx.doi.org/10.1097/00006454-199702001-00004", "ISSN": ["0891-3668"], "issn-type": [{"value": "0891-3668", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T12:57:39Z", "timestamp": 1574513859226}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 6, 1]], "date-time": "2013-06-01T00:00:00Z", "timestamp": 1370044800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Digestive and Liver Disease"], "published-print": {"date-parts": [[2013, 6]]}, "DOI": "10.1016/j.dld.2012.10.002", "type": "journal-article", "created": {"date-parts": [[2012, 11, 7]], "date-time": "2012-11-07T07:45:55Z", "timestamp": 1352274355000}, "page": "e9", "source": "Crossref", "is-referenced-by-count": 0, "title": ["An uncommon anatomic variant of the biliary tree in a potential liver donor"], "prefix": "10.1016", "volume": "45", "author": [{"given": "Harrison X.", "family": "Bai", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Digestive and Liver Disease"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1590865812003830?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1590865812003830?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 21]], "date-time": "2018-10-21T17:20:46Z", "timestamp": 1540142446000}, "score": 18.93033, "issued": {"date-parts": [[2013, 6]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2013, 6]]}, "issue": "6"}, "alternative-id": ["S1590865812003830"], "URL": "http://dx.doi.org/10.1016/j.dld.2012.10.002", "ISSN": ["1590-8658"], "issn-type": [{"value": "1590-8658", "type": "print"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}